Tis and extended tis (ETIS) sequences for improved translation initiation
Optimized nucleotide sequences modify translation initiation codon regions to enhance protein expression and reduce unintended translation, addressing inefficiencies in recombinant protein production.
Patent Information
- Application Number
- PCT/NL2026/050128
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Current methods for improving recombinant protein expression in biopharmaceuticals are inadequate in controlling and minimizing translation initiation at unintended, downstream alternative codons, leading to truncated or aberrant proteins, which affect product purity and safety.
Modifying specific nucleotides upstream and downstream of the translation initiation codon (TIC) using optimized nucleotide sequences, predicted by a deep convolutional neural network, to enhance translation initiation efficiency and reduce leaky scanning to alternative codons.
Enhances protein expression of interest and reduces translation from alternative codons, improving recombinant protein production quality and safety.
Smart Images

Figure IMGF000041_0001_TABLE 
Figure IMGF000042_0001_TABLE 
Figure IMGF000043_0001_TABLE
Abstract
Description
[0001] Title: TIS and extended TIS (eTIS) sequences for improved translation initiation
[0002] FIELD OF THE INVENTION
[0003]
[0001] This invention pertains in general to nucleic acids that encode for a protein of interest, and wherein distinct nucleotides at position -80 to +80, or at position -51 to +40, or at position -40 to + 40, all relative to the first nucleotide of the translation initiation codon (“TIC”), designated as +1 , are modified to improve protein expression of the protein of interest, and / or to reduce expression of alternative proteins or peptides initiated on an alternative TIC downstream of the main TIC encoding the protein-of-interest. This invention also pertains to methods of providing the nucleic acids according to the invention, of increasing protein expression of a protein of interest, and of reducing expression of alternative proteins.
[0004] BACKGROUND OF THE INVENTION
[0005]
[0002] The background description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.
[0006]
[0003] Recombinant protein drugs are of increasing importance in the biopharmaceutical field. With growing global demand, improving the yield of recombinant proteins while reducing production costs has become an urgent objective.
[0007]
[0004] In addition to improving the yield of the target protein, it is equally important to prevent the expression of alternative proteins or mRNAs (for example for mRNA vaccines) that may arise as a consequence of leaky scanning by the ribosomal complex (in which the ribosomal complex bypasses the intended initiation site and instead starts translation at downstream alternative TICs). Translation initiation at downstream, unintended TICs can produce truncated or aberrant proteins that may interfere with product purity, efficacy, and safety; or, when the ribosome initiated at an out of frame (OOF) TIC, cause the production of a peptide or protein with no functional resemblance to the canonical protein, possibly with alternative functions that are detrimental to cell functioning. Therefore, controlling and minimizing such off-target translation events is critical for achieving high-quality recombinant protein production.
[0008]
[0005] Current strategies for improving recombinant protein expression include vector optimization, establishment of high-producing expression systems, optimization of culture conditions, and refinement of production processes. Advances in genetic engineering, particularly genome editing technologies such as the clustered regularly interspaced short palindromic repeats / CRISPR-associated (CRISPR / Cas) system, have enabled targeted modification of expression systems with high efficiency, speed, and relatively low cost.
[0006] One factor that influences translation efficiency is the genetic context surrounding the start codon of the protein-coding sequence, in particular the so-called Kozak sequence. In eukaryotic mRNA transcripts, the Kozak sequence is a nucleic acid motif that is involved in the specificity and efficiency of translation initiation. The Kozak sequence facilitates efficient recognition of the start codon (or TIC, as used herein), which is typically the first AUG in the mRNA. The consensus Kozak sequence typically spans positions designated as -6 to -1 (being upstream of the TIC) and designated as +4 to +5 (being downstream of the TIC) relative to the first nucleotide of the TIC. In many cases, the canonical Kozak sequence or slight deviations thereof are used in expression constructs.
[0009]
[0007] In light of this, new products, compositions, methods and uses for improving protein expression, improving protein synthesis, reducing expression of alternative proteins that may arise as a consequence of leaky scanning by the ribosome, improving translation initiation from the TIC of a protein of interest, and / or reducing translation initiation at downstream, unintended alternative TICs would be highly desirable but are not yet readily available. In particular, there is a clear need in the art for reliable, efficient, and reproducible methods and sequences that allow to be used to achieve one or more of the above desirable goals. Accordingly, the technical problem underlying the present invention can been seen in the provision of such methods and sequences for complying with one or more of the aforementioned needs, or at least providing the public with a useful choice. The technical problem is solved by the embodiments characterized in the claims and herein below and is in particular useful in methods of preparing medicaments, for example wherein the medicaments are DNA, RNA, including mRNA, or proteins.
[0010] SUMMARY OF THE INVENTION
[0011]
[0008] As embodied and broadly described herein, the present invention is directed to the surprising finding that with the modification of certain nucleotides upstream and / or downstream of the TIC (or start codon) of a nucleic acid of a protein of interest, optimized nucleotide sequences may be obtained, which allow for an improved translation initiation efficiency, improved production / expression of the protein of interest, and / or reduction of translation from alternative downstream TICs, in relation to the non-modified nucleic acid sequence, thereby enhancing (recombinant) protein expression.
[0012]
[0009] The invention also relies on the surprising finding that an improved start codon recognition can be achieved and given for a particular gene sequence of interest by means of a newly developed computer-implemented method for training a deep convolutional neural network (DCNN) to predict translation-initiation activity of a given sequence, and a method for predicting translation-initiation activity for a given sequence, using the trained network.
[0010] Therefore, an aspect of the invention is a method of modifying the sequence of a nucleic acid, wherein the nucleic acid to be modified
[0013] i. comprises a first region having a sequence encoding for a protein-of-interest, and wherein the first region comprises a translation initiation codon (“TIC” or “start codon”), and wherein the position of the first nucleotide in the TIC is designated as +1 , and
[0014] ii. comprises a second region having a sequence that is directly upstream of the first region, and wherein the position of the first nucleotide upstream of the first region is designated as -1, which region is commonly named the 5’ Untranslated region (5’-UTR), and
[0015] ill. comprises a translation initiation sequence (“TIS”), wherein the TIS spans positions designated as -6 to -1 (being upstream of the TIC) and designated as +4 to +5 (being downstream of the TIC), and
[0016] iv. comprises an extended initiation sequence (“eTIS”), wherein the eTIS spans positions -80 to +80 relative to the first nucleotide of the start codon (designated as +1), preferably comprises an eTIS that spans positions -51 to -1 (being upstream of the TIC), more preferably -40 to -1 (being upstream of the TIC) and +4 to +40 (being downstream of the TIC), or preferably spans from position -40 to + 40 relative to the first nucleotide of the start codon (designated as +1 ),
[0017] and wherein the method comprises modifying the sequence of the nucleic acid at one or more nucleotides of the TIS and / or the eTIS, thereby providing a modified nucleic acid.
[0018]
[0011] As illustrated in the Examples and accompanying figures, the method according to the inventions allows for providing sequences with improved translation initiation efficiency, production / expression of the protein of interest, and / or a reduced translation of alternative downstream TICs (i.e., reduced leaking scanning), in relation to the non-modified nucleic acid sequence.
[0019]
[0012] As disclosed herein, the modifications according to the invention are modifications introduced into the nucleic acid according to the invention and that thereby may, e.g., improve expression of the protein of interest, in particular by enhancing translation initiation. Such modifications may be any modification as disclosed herein.
[0020]
[0013] The invention provides in another aspect for a method of increasing protein expression of a protein-of-interest, the method comprising modifying a nucleic acid as disclosed herein, thereby providing a modified nucleotide, and allowing expression of the protein-of-interest using the modified nucleic acid, thereby allowing increased expression of the protein of interest as compared to the unmodified nucleic acid.
[0021]
[0014] Yet in another aspect, the invention relates to a method of reducing expression of alternative proteins initiated at downstream of the TIC of the protein-of-interest in-frame or out-of-frame alternative TICs, preferably wherein the alternative TICs are present in the sequenceencoding the protein-of interest, the method comprising modifying a nucleic acid as disclosed herein, thereby providing a modified nucleotide, and allowing expression of the protein-of-interest using the modified nucleic acid, thereby favoring translation initiation from the TIC of the protein-of-interest and reducing translation initiation from the alternative TICs. / nip
[0015] In another aspect, the invention relates also to a method of increasing protein expression of a protein-of-interest and / or of reducing expression of alternative proteins initiated at in-frame or out-of-frame alternative TICs downstream of the TIC of the protein-of-interest, the method comprising:
[0022] a) identifying the natural sequence of the nucleic acid encoding the protein of interest, and including the TIC, TIS and eTIS;
[0023] b) modifying the natural sequence of the nucleic acid in accordance with the method of modifying the sequence of a nucleic acid as disclosed in any of the aspects and embodiments herein, thereby providing a modified nucleic acid; and
[0024] optionally, allowing expression of the modified nucleic acid.
[0025] The invention also provides for modified nucleic acids as defined in any of the previous aspects, preferably wherein the sequence of the TIS and TIC in the modified nucleic acid is modified to ACCACA ATG GC (SEQ ID NO: 1) or, preferably, ACCAAA ATG GC (SEQ ID NO: 2), or wherein the sequence of the TIS and TIC in the modified nucleic acid is ACCACA ATG GC (SEQ ID NO: 1) or, preferably, ACCAAA ATG GC (SEQ ID NO: 2), and / or wherein the modified nucleic acid comprises a sequence selected from SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, and / or wherein the modified nucleic acid comprises one or more of the following motifs: AAA motif at position +16 to +18; a CCC motif at position +7 to +9; a CTAAA motif at position +10 to +14; a AAAAA motif at position -14 to -10; and / or a UUUUUUUUUUU (SEQ ID NO: 16) motif at position -37 to -27.
[0026]
[0016] In another aspect, the invention relates also to a cell, plasmid, expression construct, vector, (m)RNA, vaccine or pharmaceutical composition comprising a modified nucleic acid as defined in any one of the previous aspects and corresponding embodiments of the description.
[0027]
[0017] Another aspect of the invention is a method of manufacturing a pharmaceutical composition comprising a modified nucleic acid or a protein-of-interest, the method comprising modifying a nucleic acid according to method of any one of the previous aspects, thereby providing a modified nucleic acid, and including the modified nucleic acid, or the protein-of-interest expressed therefrom, in the pharmaceutical composition.
[0028] BRIEF DESCRIPTION OF THE DRAWINGS
[0029]
[0018] Embodiments of the invention are further described hereinafter with reference to the accompanying drawings, in which:
[0019] Figure 1. This Figure shows eTIS optimization can be used to reduce leaky scanning of canonical TICs in human and therapeutic mRNAs in HEK293T cells. A. Sequence optimization based on constant eTIS in endogenous human mRNA sequences. B. Same as A for where AUG (TIC) was changed into CUG or GUG. TIS was optimized to ACCAAA. C. TIS optimization (left) has a similar effect on start codon recognition as eTIS optimization (right). D. Comparison between TIS and eTIS optimization in the same gene sequence; eTIS optimization often outperforms TIS optimization. E. Same as in A for therapeutic mRNAs. F. Same as in E with the addition that nucleotides -6 to -1 of the TIS are changed to ACCAAA. G. Same as D for therapeutic mRNAs. H. eTIS optimization of therapeutic mRNAs enhances the expression from the main TIC. I. Same as F, for COS7 cells. J. Same as F, for CHO-K1 cells. K. Quantification of IRES-driven translation for constructs shown in g, containing weak or strong distal eTIS sequences. Data is represented as the mCherry / GFP fluorescence ratio. Bars represent the mean across five biological replicates (N = 5), with individual replicates shown as dots. Fold changes in fluorescence ratios between sequences sharing the same IRES are indicated. Statistical significance was assessed using a Welch’s two-sample t-test. ** denotes P < 0.01
[0030]
[0020] Figure 2: Comparison of start codon recognition between all modifications at all the positions and the sum of modifications. Introducing all motifs simultaneously results in more start codon recognition than the sum of the individual motifs (i.e., synergy).
[0031]
[0021] Figure 3. Improving start codon recognition with a deep convolutional neural network. In A Dotplot representing the correlation between the predicted (x-axis) and measured (y-axis) leaky scanning values based on the RiboScan reporter. In B In silico evolution of the eTIS sequence shows that deoptimization increases leaky scanning (higher GFP expression), whereas optimization reduces it, as accessed with the RiboScan assay scanning values based on the RiboScan reporter.
[0032]
[0022] Figure 4. Gene sequences beyond the TIS control start codon recognition A., Schematic of the RiboScan reporter mRNA. (Top) Reading frame is indicated for different mRNA features. T2A ‘Stop-Go’ sequences are indicated in grey. The first T2A sequence is in frame +1 (F1), the latter two in the main frame (F0). Middle, when the first start codon (main start codon, in F0) is positioned in a strong sequence context, ribosomes initiate on the first start codon and produce mCherry and the enzyme providing puromycin resistance. Bottom, when the first start codon is positioned in a poor sequence context, ribosomes continue scanning and initiate on the downstream start codon (F1 ) to produce GFP. Dark gray ribosome are undergoing translation initiation. B. Schematic of high-throughput analysis of the RiboScan reporter assay. Four hypothetical cells are shown
[0023] Figure 5. The local sequence context of the gene supports efficient start codon recognition A. Box plots representing the logs fold changes in start codon recognition upon exchanging the native TIS to three different foreign TISes of the same strength . Data is separated by 5’UTR length. The horizontal line in the box represents the median value, the box indicates the 25%-75% range, and whiskers indicate the 5%-95% range. B. Distributions of the translation framed of the first downstream AUG relative to the mainframe start codon of genes that show less (Left) or more (Middle) leaky scanning upon the introduction of foreign TISes. As a control, the distribution for all mRNA transcripts (Ensembl canonical transcripts, Ensembl release 110, July 2023) is plotted (Right). The genes with less leaky scanning are enriched in downstream in frame AUGs. C. Box plot depicting the obtained GFP intensities of TIS sequences in their native context or foreign TISes introduced in the transcripts. For every TIS strength, at least 10 different native TISes must have been measured. Note that for each native TIS group many different TIS sequences of the same strength are included in the box, while for the foreign TIS data only one foreign TIS sequence was measured per TIS strength. D. Quantification of GFP / mCherry ratios for RiboScan constructs containing combinations of strong (S) or weak (W) distal eTIS and TIS elements. Bars represent the mean GFP / mCherry ratio across four replicates, with individual replicates shown as dots. Fold changes in fluorescence ratios between sequences sharing the same TIS are indicated. Statistical significance was assessed using a Welch’s two-sample t-test. * denotes P < 0.05, *** P < 0.001, **** P < 0.0001.E-G, Log2(Fold Change) in GFP expression of the RiboScan reporter when comparing the optimal nucleotide with the least optimal nucleotide for indicated positions within the TIS (E) and distal eTIS (F-H) H-J. Each dot corresponds to an mRNA sequence carrying the specified substitution at the indicated position
[0033] Figure 6. Distal sequences influence start site recognition. A. The number of genes for which start codon recognition is affected by the introduction of a mutation increases as the mutations are introduced closer to the TIS. Each dot in the plot corresponds to a 5 nucleotide mutation tile, except for the fourth and the third last data points, which respectively contain four nucleotides (nucleotides -10 to -7) and three nucleotides (+6 to +8). The genes that were significantly affected by the introduction of the mutation were identified with differential gene expression analysis (See Methods). The fraction of significantly changing genes out of the total number of genes with available data at each of the positions was plotted. The data point which exclusively contains TIS bases (-5 to -1) is excluded from the graph. The black vertical lines represents the typical size of a ribosomal footprint. The data is separated by 5’UTR length. The lines and corresponding shaded areas represent linear fits through the data and the 95% confidence intervals of the regression lines. B. Same as in (A.) with a longer fraction of the CDS included in the reporter. Even mutations downstream of the start codon influencethe efficiency of start codon recognition. C. Same as in (A.) for single nucleotide substitutions. All single nucleotide substitutions that are located in each of the 5-nucleotide mutations tile of (A.) were aggregated and grouped per gene. The fraction represents the number of genes for which at least one single nucleotide substitution within the 5-nucleotide tile caused a significant change in start codon recognition out of the total number of genes assessed.
[0034]
[0024] Figure 7. Distal sequences influence start codon recognition independently of the TIS. A. Distal mutations provide a similar change in start codon recognition with different TIS sequences. Bar plot of the Iog2fold changes in start codon recognition in several sequence variants. The Ensembl canonical transcript name, from which the sequence is obtained, is indicated between brackets above the plot.. The data is grouped by TIS variant. All TISes have the same strength as the native TIS sequence. The native TIS is indicated as WT TIS. (SEQ ID NO: 27, AAGACCAUGGG represented in the sequence listing as AAGACCATGGG; SEQ ID NO: 28, CCAGCCAUGCU represented in the sequence listing as CCAGCCATGCT; SEQ ID NO: 29, CGGAACAUGUU represented in the sequence listing as CGGAACATGTT; SEQ ID NO: 30, GALJAAGAUGAU represented in the sequence listing as GATAAGATGAT; SEQ ID NO: 31, ACGGGCAUGCU represented in the sequence listing as ACGGGCATGCT; SEQ ID NO: 32, AGCGUGAUGCG represented in the sequence listing as AGCGTGATGCG; SEQ ID NO: 33, CUGCAAAUGUG represented in the sequence listing as CTGCAAATGTG; and SEQ ID NO: 34 GACCACAUGUU represented in the sequence listing as GACCACATGTT) B. Boxplot representing the changes in start codon recognition changes between foreign TISes with and without distal mutations with native TISes with and without distal mutations. The data was separated per 5’UTR length group and whether the distal mutation with the native TIS was reducing (Left) or enhancing the efficiency of start codon recognition (Right). The horizontal line in the box represents the median value, the box indicates the 25%-75% range, and whiskers indicate the 5%-95% range. A value of 1 indicates that the distal mutations reduce (Left) or enhance (Right) start codon recognition in the foreign TISes to a similar extent as in the native TIS. C. Box plot representing the distributions of Iog2 fold changes in start codon recognition per 5’UTR length group and per type of mutation. The top plot represents the distributions of Iog2 fold changes in start codon recognition in case the original mutations caused a reduction in the efficiency of start codon recognition. Bottom plot represents the distributions of Iog2 fold changes in the efficiency of start codon recognition in case the original mutations enhanced the efficiency of start codon recognition. The horizontal line in the box represents the median value, the box indicates the 25%-75% range, and whiskers indicate the 5%-95% range.
[0035]
[0025] Figure 8. The nucleotide identity of the +6 nucleotide influences the efficiency of start codon recognition. Box plots representing the GFP values grouped per +6 nucleotidein a large set of different human transcripts that share the same foreign TIS sequence. TIS and TIS strength are indicated above each plot. The horizontal line in the box represents the median value, the box indicates the 25%-75% range, and whiskers indicate the 5%-95% range. (SEQ ID NO:35, CCACUUAUGAC represented in the sequence listing as CCACTTATGAC; SEQ ID NO: 36, GGAAAAAUGCG represented in the sequence listing as GGAAAAATGCG; SEQ ID NO: 37, CUUUCGAUGUC represented in the sequence listing as CTTTCGATGTC; and SEQ ID NO: 38, UCUGUGAUGGC represented in the sequence listing as TCTGTGATGGC).
[0036]
[0026] Figure 9. Genome-wide nucleotide enrichments in the eTIS. A. The effect of the -2C to A substitution on leaky scanning is dependent on the identity of the nucleotide at the -1 position. When -1 is a purine, adenine at -2 reduces leaky scanning relative to cytosine (left), when -1 is a pyrimidine, cytosine at -2 reduces leaky scanning relative to adenine (right). Each dot corresponds to an mRNA molecule carrying the specified substitution at the indicated position. B. Same as (A.) for a -1C to A substitution, with data separated by nucleotide type (purine, pyrimidine) at the -2 position.
[0037] DESCRIPTION
[0038] Definitions
[0039]
[0027] A portion of this disclosure contains material that is subject to copyright protection (such as, but not limited to, diagrams, device photographs, or any other aspects of this submission for which copyright protection is or may be available in any jurisdiction.). The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or patent disclosure, as it appears in the Patent Office patent file or records, but otherwise reserves all copyright rights whatsoever.
[0040]
[0028] Various terms relating to the methods, compositions, uses and other aspects of the present invention are used throughout the specification and claims. Such terms are to be given their ordinary meaning in the art to which the invention pertains, unless otherwise indicated. Other specifically defined terms are to be construed in a manner consistent with the definition provided herein. Although any methods and materials similar or equivalent to those described herein can be used in the practice for testing of the present invention, the preferred materials and methods are described herein.
[0041]
[0029] For purposes of the present invention, the following terms are defined below.
[0042]
[0030] As used herein, the indefinite articles “a” and “an” are synonymous with “at least one” or “one or more.” Unless indicated otherwise, definite articles used herein, such as “the” also include the plural of the noun.
[0031] As used herein, references to a DNA sequence refer to the nucleotide sequence of a coding strand. References to an RNA sequence refer to the sequence as may be transcribed from the template strand of the corresponding DNA, such that the RNA sequence is identical to the coding strand sequence except that uracil (U) replaces thymine (T). For example, if the coding strand DNA sequence is 5'-ATGCCG-3', the corresponding RNA sequence is 5'-AUGCCG-3'. It will be understood by the skilled person that where reference is made to a certain region in the mRNA, such as a translation initiation sequence (TIS), this includes the corresponding sequence in the DNA, and visa versa.
[0043]
[0032] As used herein, "efficiency of translation initiation codon recognition" refers to the relative effectiveness with which a ribosome identifies and initiates translation at a given translation initiation codon within a messenger RNA (mRNA) molecule. Efficiency of translation initiation codon recognition can be measured by the level of protein expression resulting from initiation at that codon under defined conditions. In one example, efficiency of translation initiation codon recognition may be assessed by introducing sequence changes in the mRNA and comparing the resulting levels of translation or protein expression. In another example, leaky scanning may be used to evaluate relative initiation efficiencies, whereby ribosomes bypass upstream initiation codons with suboptimal contexts and initiate translation at downstream codons, allowing for comparative analysis of codon recognition efficiency.
[0044]
[0033] As used herein, "extended translation initiation sequence" or “eTIS” refers to a nucleotide sequence within a messenger RNA (mRNA), and / or the corresponding coding DNA sequence, that includes the translation initiation sequence (TIS), and additional upstream and downstream sequences, collectively spanning positions -80 to +80 or -51 to +40, or - 40 to + 40 , relative to the translation initiation codon, wherein the first nucleotide of the initiation codon is designated as position +1. The "extended translation initiation sequence" does not include the translation initiation codon.
[0045]
[0034] As used herein, "increased protein expression" refers to a higher level of production of a protein-of-interest, as compared to a suitable control. Such an increase may be measured at the protein level, for example by immunoassay, activity assay, or mass spectrometry. Unless otherwise indicated, an increase of 1.05-fold or more, preferably 1.1-fold or more, more preferably 1.2-fold or more, relative to the control is considered to constitute increased protein expression.
[0046]
[0035] As used herein, "increased translation initiation efficiency" refers to a higher efficiency of initiation of translation at a specified translation initiation codon, as compared to a suitable control. Such an increase may be determined, for example, by measuring the resulting level of protein expression or by reporter assays designed to assess initiation efficiency. Unless otherwise indicated, an increase of 1.05-fold or more, preferably 1.1-fold or more, morepreferably 1.2-fold or more is considered to constitute increased translation initiation efficiency.
[0047]
[0036] As used herein, "leaky scanning" refers to a mechanism wherein during translation initiation a ribosome, while scanning the messenger RNA (mRNA) in the 5' to 3' direction, bypasses a translation initiation codon (which can be the translation initiation codon that encoded the canonical protein isoform), and continues scanning until initiating translation at a downstream codon. This phenomenon may occur when the upstream initiation codon is in a suboptimal sequence context, thereby reducing its recognition efficiency by the ribosome. Leaky scanning can result in the production of alternative protein isoforms from a single mRNA transcript, or completely different proteins / peptides if the alternative translation initiation codon is positioned in a different reading frame. In the context of the present disclosure, leaky scanning may be used to compare relative efficiencies of translation initiation codon recognition.
[0048]
[0037] As used herein, a "recombinant nucleic acid" refers to a nucleic acid molecule, such as DNA or RNA, that has been artificially constructed, modified, or generated to contain sequences that are not naturally occurring, have been altered from their native form, or are derived from different sources, including different species, strains, or synthetic origins. Recombinant nucleic acids may be produced using methods including genomic engineering, recombinant DNA / RNA technology or chemical synthesis. In preferred embodiments of the invention, the nucleic acids herein are recombinant nucleic acids.
[0049]
[0038] As used herein, "translation initiation" refers to the process by which the ribosome assembles on a messenger RNA (mRNA) molecule and begins protein synthesis by recognizing the translation initiation codon (TIC) within the mRNA, positioning the initiator tRNA, and establishing the correct reading frame for subsequent elongation of the polypeptide chain. In more detail, the ribosome selects the correct start codon and starts protein synthesis: 1. pre-initiation complex gets recruited to the mRNA; 2. PIC scans mRNA for start codons; 3. Start codon get recognized. 3; large subunit is recruited; 4. Translation moves to elongation phase where the protein is being synthesized.
[0050]
[0039] As used herein, "translation initiation codon" or “TIC” refers to a nucleotide codon (three nucleotides) within a messenger RNA (mRNA) sequence and / or the corresponding coding DNA sequence, that signals the start of translation by the ribosome, typically corresponding to the codon AUG, which encodes methionine in eukaryotes, and defines the reading frame for subsequent polypeptide synthesis.
[0051]
[0040] As used herein, "translation initiation sequence" or “TIS” refers to a nucleotide sequence within a messenger RNA (mRNA), and / or the corresponding coding DNA sequence, that flanks, but does not include, the translation initiation codon (TIC). The translation initiationsequence consists of a total of eight nucleotides, specifically spanning positions -6 to -1 upstream and +4 to +5 downstream of the translation initiation codon, wherein the first nucleotide of the initiation codon is designated as position +1.
[0052]
[0041] As used herein, the word “comprise” or variations thereof such as “comprises” or “comprising” will be understood to include a stated element, integer or step, or group of elements, integers or steps, but not to exclude any other element, integer or steps, or groups of elements, integers or steps. The verb “comprising” includes the verbs “essentially consisting of” and “consisting of”.
[0053]
[0042] As used herein, the term “determining”, for example determining translation initiation efficiency, improved production / expression of the protein of interest, and / or reduction of translation from alternative downstream TICs, includes measuring, analyzing, estimating, following, and providing amounts / values, for example, using conventional means and / or techniques.
[0054] Detailed description
[0055]
[0043] The invention is defined herein, and in particular in the accompanying claims. Subjectmatter which is not encompassed by the scope of the claims does not form part of the present claimed invention.
[0056]
[0044] Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment envisaged herein. Thus, appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures or characteristics may be combined in any suitable manner, as would be apparent to a skilled person from this disclosure, in one or more embodiments. Furthermore, while some embodiments described herein include some, but not other features included in other embodiments, combinations of features of different embodiments are also envisaged herein, and form different embodiments, as would be understood by those in the art. All such embodiments are directly and unambiguously disclosed.
[0057]
[0045] It is contemplated that embodiments described herein in relationship to any method, use, or composition can be implemented with respect to any other method, use or composition described herein. Embodiments discussed in the context of methods, use and / or compositions of the invention may be employed with respect to any other method, use or composition described herein. Thus, an embodiment pertaining to one method, use or composition may be applied to other methods, uses and compositions of the invention as well.
[0046] Any references in the description to methods of treatment refer to the compounds, pharmaceutical compositions, and medicaments of the present invention for use in a method for treatment of the human (or animal) body by therapy.
[0058]
[0047] As embodied and broadly described herein, the present invention is directed to the surprising finding that with the modification of certain nucleotides upstream and / or downstream of the TIC (or start codon) of a nucleic acid of protein of interest, optimized nucleotide sequences may be obtained, which allow for an improved translation initiation efficiency, improved production / expression of the protein of interest, and / or reduction of translation from alternative downstream TICs, in relation to the non-modified nucleic acid sequence, thereby enhancing protein expression, for example, recombinant protein expression.
[0059]
[0048] The present invention addresses these challenges by providing optimized nucleotide sequences, upstream and / or downstream of the TIC (or start codon) of a protein of interest. Such optimization may improve translation initiation efficiency, production / expression of the protein of interest, and / or reduces translation from alternative downstream TICs, thereby enhancing recombinant protein expression.
[0060]
[0049] An aspect of the invention is a method of modifying the sequence of a nucleic acid, wherein the nucleic acid to be modified
[0061] i. comprises a first region having a sequence encoding for a protein-of- interest, and wherein the first region comprises a translation initiation codon (“TIC” or “start codon”), and wherein the position of the first nucleotide in the TIC is designated as +1, and
[0062] ii. comprises a second region having a sequence that is directly upstream of the first region, and wherein the position of the first nucleotide upstream of the first region is designated as -1 , which region is commonly named the 5’ Untranslated region (5’-UTR), and
[0063] iii. comprises a translation initiation sequence (“TIS”), wherein the TIS spans positions designated as -6 to -1 (being upstream of the TIC) and designated as +4 to +5 (being downstream of the TIC), and
[0064] iv. comprises an extended initiation sequence (“eTIS”), wherein the eTIS spans positions -80 to +80 relative to the first nucleotide of the start codon (designated as +1), preferably comprises an eTIS that spans positions -51 to -1 (being upstream of the TIC), more preferably -40 to -1 (being upstream of the TIC) and +4 to +40 (being downstream of the TIC), or preferably spans from position - 40 to + 40 relative to the first nucleotide of the start codon (designated as +1),and wherein the method comprises modifying the sequence of the nucleic acid at one or more nucleotides of the TIS and / or the eTIS, thereby providing a modified nucleic acid.
[0065]
[0050] The modification may be a substitution of one or more nucleotides with another nucleotide (A, C, T, G (in DNA) or A, C, G, U (in RNA)) and may occur within coding regions, non-coding regions, regulatory elements, or any combination thereof.
[0066]
[0051] In certain embodiments the number of modifications is selected from 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more. Preferably the modifications are introduced at least upstream of the TIC. Preferably the modifications are introduced upstream and downstream of the TIC.
[0067]
[0052] In certain embodiments, method comprises modifying the sequence of the nucleic acid at one or more nucleotides of the TIS. In another embodiment, the method comprises modifying the sequence of the nucleic acid at one or more nucleotides of the eTIS. In other certain embodiments, method comprises modifying the sequence of the nucleic acid at one or more nucleotides of the TIS and eTIS.
[0068]
[0053] In certain embodiments of the invention, there is provided for a method according to the invention, wherein the modified nucleic acid is present in a eukaryotic cell, preferably a human cell, or wherein the modified nucleic acid is introduced in a eukaryotic cell, preferably an animal cell.
[0069]
[0054] In accordance with the invention, the modified nucleic acid may be present outside or inside a cell. For example, modification of the nucleic acid to provide for the modified nucleic acid may be performed outside a cell or inside / within a cell. In embodiments wherein the nucleic acid is modified outside the cell, the modified nucleic acid may be introduced in a cell by any suitable means. As will be understood by the skilled person, a modification, relative to the initial sequence, may also be provided by synthesis of the nucleic acid comprising the modification.
[0070]
[0055] In certain embodiments, the modified nucleic acid is located within a eukaryotic cell. Preferably, the cell is an in vitro cell, i.e. a cell that is maintained and grown, outside of its natural biological environment, for example outside the animal body. The eukaryotic cell may be an animal cell, such as a mammalian, avian, reptilian, amphibian, or piscine cell, preferably a mammalian cell, such as a primate cell, and more preferably a human cell. Other non-limiting examples include rodent (mouse, rat), canine, feline, primate, bovine, porcine, and ovine, cells. In some embodiments, the cells are monkey cells, such as COS 7 cells. In some embodiments, the cells are hamster cells, such as Chinese hamster ovary cells. In some embodiments, the cells are yeast cells, for example particular yeast cells or yeast strains suitable for theproduction of proteins such as, but not limited to, Saccharomyces cerevisiae or strains thereof. The cell may be a primary cell or may be a cell line. Preferably, the cell is a cell that is commonly used for the production of proteins, in particular for the production of therapeutic proteins. Other proteins of interest may be proteins encoded by nucleic acid (e.g. mRNA) vaccines and proteins of interest at industrial level.
[0071]
[0056] The modified nucleic acid may be stably integrated into the genome of the eukaryotic cell, or preferably, may be present non-integrated, for example as an episomal element, for example comprised in a plasmid or expression vector. The modified nucleic acid may be an RNA (including mRNA) and / or DNA molecule and may be linear or circularized. In preferred embodiments, the modified nucleic acid is capable of being expressed in the eukaryotic cell to produce one or more functional RNAs (including mRNAs) or protein products.
[0072]
[0057] In other embodiments, the modified nucleic acid is introduced into a eukaryotic cell by any suitable delivery method known in the art. Such methods include, without limitation, transfection, electroporation, microinjection, lipofection, viral vector-mediated delivery, or physical delivery techniques such as particle bombardment. In certain embodiments, introduction of the modified nucleic acid into the eukaryotic cell is performed in vitro, ex vivo, or in vivo, preferably in vitro. In some embodiment, the modified nucleic acid in administered to a human subject, for example wherein the modified nucleic acid is a therapeutic DNA and / or RNA molecule, for example a vaccine.
[0073]
[0058] In certain embodiments of the invention, there is provided for a method according to the invention, wherein the modification does not change the amino acid sequence of the encoded protein-of-interest. Similarly, in embodiments of the invention, there is provided for a nucleic acid molecule wherein the at least one modification does not change the encoded amino acid
[0074]
[0059] In accordance with the invention, the modification introduced into the nucleic acid comprises a change in the identity of one or more nucleotides in the nucleic acid (i.e., wherein any one of an adenine (A), thymine (T), cytosine (C), and guanine (G) in the case of DNA, or adenine (A), uracil (U), cytosine (C), and guanine (G) in the case of RNA is modified into any one of other nucleotides, thus providing a modified nucleic acid). Such modifications may be silent, resulting in no change to the amino acid sequence of the protein-of-interest that is comprised in the first region, for example due to redundancy of the genetic code, of because the modification is not within the coding region of the protein of interest. Alternatively, such modification may lead to a modification in the amino acid sequence of the protein-of-interest, for example as the consequence of a change in a codon comprised in the region encoding the protein of interest. In certain preferred embodiments, the amino acid sequence of the protein of interest is not modified as a consequence of the method according to the invention. In certainpreferred embodiments, the amino acid sequence of the protein of interest is modified as the consequence of the method according to the invention.
[0075]
[0060] In embodiments wherein the amino acid sequence of the protein of interest is modified, the resulting protein preferably retains substantially the same biological activity as the original protein. Alternatively, the modified protein may exhibit enhanced or increased biological activity or stability compared to the original protein. Such activities of the protein of interest may include, but is not limited to, enzymatic function, binding affinity, signaling capability, antigenic properties, or other relevant functional properties associated with the protein.
[0076]
[0061] In certain embodiments of the invention, there is provided for a method according to the invention, wherein
[0077] a) the modified nucleic acid, or eukaryotic cell comprising the modified nucleic acid, exhibits increased expression of the protein-of-interest as compared to the unmodified nucleic acid;
[0078] b) the modified nucleic acid, or eukaryotic cell comprising the modified nucleic acid, exhibits reduced expression of alternative proteins initiated at downstream in-frame or out of frame alternative TICs, preferably wherein the alternative TICs are present in the sequence encoding the protein-of interest; and / or
[0079] c) the modified nucleic acid, or eukaryotic cell comprising the modified nucleic acid, exhibits increased translation efficacy as compared to the unmodified nucleic acid.
[0080]
[0062] In accordance with the invention, the method according to the invention of modifying a nucleic acid as described herein, may provide for a modified nucleic acid as described herein and that exhibits, in comparison to the non-modified nucleic acid, increased expression of the protein-of-interest, increased translation efficacy, and / or reduced expression of alternative proteins initiated at downstream in-frame or out of frame alternative TICs, preferably wherein the alternative TICs are present in the sequence encoding the protein-of interest as compared to the unmodified nucleic acid.
[0081]
[0063] The skilled person understands that the properties of a modified nucleic acid as described herein can be determined using routine techniques. For example, to determine whether a modified nucleic acid exhibits increased expression of the protein of interest relative to an unmodified nucleic acid, standard expression assays may be employed. Such assays include, but are not limited to methods disclosed herein, Western blotting, ELISA, flow cytometry, or reporter gene assays, which enable direct or indirect measurement of protein levels in cells transfected / transduced with the nucleic acid. For example, translation efficacy can be determined by methods such as those disclosed herein, and / or in vitro translation assays, providing insight into the efficiency of protein synthesis from the nucleic acid. For example, determining reduced expression of alternative proteins initiated at downstream in-frame or out-of-frame alternative translation initiation codons (TICs), preferably present within the sequence encoding the protein of interest, can be performed with methods as disclosed herein, including leaky scanning assays, Western blotting, or reporter constructs that distinguish initiation events. Such assays are well within the capabilities of the skilled person and can be routinely performed without undue experimentation.
[0082]
[0064] Unless otherwise indicated, an increase of 1.05-fold or more, preferably 1.1 -fold or more, more preferably 1.2-fold or more, relative to the control is considered to constitute increased protein expression. For example, protein expression may be increased, with increasing preference, by 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% or more, as compared to the control, unmodified, nucleic acid.
[0083]
[0065] Unless otherwise indicated, an increase of 1.05-fold or more, preferably 1.1 -fold or more, more preferably 1.2-fold or more is considered to constitute increased translation initiation efficiency. For example, translation initiation may be increased, with increasing preference, by 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% or more, as compared to the control, unmodified, nucleic acid.
[0084]
[0066] Unless otherwise indicated, a decrease in expression of alternative proteins initiated at downstream in-frame or out-of-frame alternative translation initiation codons (TICs), preferably present within the sequence encoding the protein of interest, by, with increasing preference, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more, including 100%, as compared to the control, unmodified, nucleic acid is considered to constitute a decreased expression of alternative proteins initiated at downstream in-frame or out-of-frame alternative translation initiation codons (TICs).
[0085]
[0067] In certain preferred embodiments the alternative TICs are present in the sequence encoding the protein-of interest.
[0086]
[0068] In preferred embodiments of the invention, there is provided for a method according to the invention, wherein the nucleic acid and / or modified nucleic acid is a recombinant nucleic acid, and / or wherein the nucleic acid and / or modified nucleic acid is a RNA molecule,preferably mRNA molecule, or DNA molecule, preferably a DNA molecule encoding the RNA molecule, more preferably wherein the nucleic acid and / or modified nucleic acid is a therapeutic nucleic acid, preferably a therapeutic DNA molecule, a therapeutic RNA molecule, or a therapeutic mRNA molecule.
[0087]
[0069] In accordance with the invention, the nucleic acid and / or modified nucleic acid is a DNA molecule (comprising A, T, C, G) or RNA molecule (comprising A, U, C, G), preferably a mRNA molecule. In accordance with the invention, the modified nucleic acid according to the invention is preferably a recombinant nucleic acid.
[0088]
[0070] The nucleic acid or modified nucleic acid may comprise an RNA molecule, preferably an mRNA molecule, or a DNA molecule, preferably a DNA molecule encoding the RNA / mRNA molecule.
[0089]
[0071] More preferably, the nucleic acid or modified nucleic acid is a therapeutic nucleic acid, including but not limited to a therapeutic DNA molecule, a therapeutic RNA molecule, or a therapeutic mRNA molecule. Such therapeutic nucleic acids are intended for use in the prevention, treatment, or management of disease or disorder in a subject. Examples of therapeutic nucleic acids include, but are not limited to, nucleic acids used in vaccines and gene therapy. For example, the nucleic acids may be mRNA vaccines, for example, encoding antigens for the prevention or treatment of infectious diseases, or may be DNA or RNA molecules used in gene replacement or gene editing therapies. For example, therapeutic nucleic acids may include constructs for antibody expression, or chimeric antigen receptor expression in cell therapy, or nucleic acids encoding therapeutic proteins or peptides.
[0090]
[0072] In addition to the modification(s) according to the invention (i.e. a modification replacing a nucleotide with another nucleotide), the nucleic acid or modified nucleic acid according to the invention may further comprise one or more additional modifications that serve purposes other than those described herein in the context of the invention disclosed herein. For example, such modifications may enhance the stability or reduce the breakdown of the nucleic acid (modified nucleic acid), for example in the case of RNA molecules. Examples of such additional modifications include, but are not limited to, 1-methylpseudouridine (l-mT1), pseudouridine (1), 5-methylcytosine (5mC), 2'-O-methyl nucleotides, or N1-methyladenosine (m1A). These modifications are known to the skilled person and shown to improve nuclease resistance and / or reduce innate immune activation.
[0091]
[0073] In certain embodiments of the invention, there is provided for a method according to the invention, wherein the nucleic acid or modified is comprised in a plasmid, vector or expression construct.
[0092]
[0074] Within the current invention, a plasmid is a small, circular, double-stranded DNA molecule; a vector refers to any nucleic acid molecule used as a vehicle to transfer geneticmaterial into a host cell, and may include, in addition to plasmids, bacteriophages, artificial chromosomes, and viral vectors (e.g., lentivirus, adenovirus); and a an expression construct is a type of vector specifically designed to drive the expression of a gene of interest in a host cell.
[0093]
[0075] In certain embodiments of the invention, the nucleic acid or modified nucleic acid is comprised within a plasmid. In certain embodiments of the invention, the nucleic acid or modified nucleic acid is comprised within a vector. In certain embodiments of the invention, the nucleic acid or modified nucleic acid is comprised within an expression construct (or expression vector).
[0094]
[0076] The nucleic acid or modified nucleic acid may be in linear or circular form. Circular constructs, such as circular plasmids may be useful for stable maintenance and efficient expression in host cells, while linear constructs may be desirable in applications requiring transient expression or specific delivery methods, such as mRNA transfection. Suitable plasmids, vectors or expression constructs, are well known to the skilled person. These constructs are designed to facilitate expression of the protein of interest in a suitable host cell and may further comprise regulatory elements such as promoters, enhancers, and terminators. Such constructs are preferably recombinant constructs.
[0095]
[0077] In certain embodiments, there is provided for a method according to the invention, wherein the protein-of-interest is an antigen.
[0096]
[0078] In accordance with the invention, the protein of interest may be any type of protein. For example, the protein of interest may be an enzyme, an antigen, an antibody, a receptor, a transport protein, a structural protein, a regulatory protein, a signaling molecule, a hormone, or a protein that may be present in a complex.
[0097]
[0079] However, in a preferred embodiment, the protein of interest is an antigen. As the skilled person understands, a modified nucleic acid according to the invention, encoding an antigen may serve as a therapeutic agent, for example in the form of a vaccine, for example a DNA or RNA vaccine. Such nucleic acids can be introduced into a subject to direct the expression of the antigen in vivo, thereby eliciting an immune response against the antigen. This immune response can provide protection against infectious agents, tumors, or other diseases associated with the antigen.
[0098]
[0080] In another embodiment, there is provided for a method according to the invention, wherein one or more of:
[0099] a) a U, C or G at one or more of the positions -14 to -9 in the nucleic acid is modified to an A;
[0100] b) an A, C or G at one or more of the positions -35 to -18 in the nucleic acid is modified to an U;c) a U, C or G at one or more of the positions +12 to +18 in the nucleic acid is modified to an A; and / or
[0101] d) an A, U or C at one or more of the positions +9 to +11 in the nucleic acid is modified to a G,
[0102] or wherein the modified nucleic acid comprises
[0103] e) an A at one or more of the positions -14 to -9;
[0104] f) a U at one or more of the positions -35 to -18;
[0105] g) an A at one or more of the positions +12 to +18; and or
[0106] h) a G at one or more of the positions +9 to +11
[0107]
[0081] In certain embodiments, when the one or more modifications are in a) to f) the sequence encoding for a protein of interest is not changed. In other embodiments, when the one or more modifications are in any one or both of g) and h), independently of the presence of one or more modifications in any of a) to f), the sequence encoding for a protein of interest may be changed. In certain embodiments, when the sequence encoding for a protein of interest is changed, the resulting expressed protein may or may not contain a change of one or more amino acids. In certain embodiments, the expressed protein does not contain a change of amino acid, for example because the nucleotide modification(s) in the sequence encoding the protein provide for the same amino acid due to the amino acid degenerate code. In other embodiments, when the sequence encoding for a protein of interest is changed in accordance with the method according to the invention, in the resulting expressed protein one or more amino acids are changed, preferably provided that the functionality of the protein is not altered, or, in case of a therapeutic protein, does not cause any adverse effect once translated and expressed in a cell or organism as the consequence of the change in amino acids.
[0108]
[0082] In yet another embodiment of the method of the invention, one or more nucleotides are modified, and wherein the nucleotide at a first position indicated in Tables 1 , 2 or 3 is modified to a nucleotide for which a lower value is indicated at the corresponding position in any one of Table 1, Table 2 or Table 3, preferably wherein the nucleotide at a first position indicated in Tables 1, 2 or 3 is modified to a nucleotide for which a lower value is indicated at the corresponding position in the same Table 1 , Table 2 or Table 3.
[0109]
[0083] As an example, if at position -37 of the nucleic acid sequence to be modified there is a cytosine (C), the nucleotide may be changed according to Table 1 to an adenine (A) or uracil (U), because the indicated values are, respectively, -0,15 for A and -0.14 for U, whereas the indicated value for C at this position is 0,10.
[0110]
[0084] In a preferred embodiment of the method of the invention, one or more nucleotides are modified, and wherein the nucleotide at a first position indicated in Tables 1 is modified to a nucleotide for which a lower value is indicated at the corresponding position in Table 1.
[0085] Preferably, the nucleotide at a given position is modified to the nucleotide with the lowest number on that position as shown in Table 1, Table 2 or Table 3, preferably Table 1. As an example, if at position -37 of the nucleic acid sequence to be modified there is a cytosine (C), the nucleotide may be changed according to Table 1 to an adenine (A) or uracil (U), preferably A, because the indicated values are, respectively, -0,15 for A and -0.14 for U, whereas the indicated value for C at this position is 0,10.
[0111]
[0086] In Tables 1 , 2 and 3 below the position within the sequence is indicated in the first row, and the values for A, C, G, U are provided per position in the column per position. Lower values in a column (i.e. for a given position) indicate a positive contribution in translation efficiency relative to a higher value in the same column.
[0112]
[0087] Table 1
[0113] -40 -39 -38 -37 -36 -35 -34 -33 -32 -31 -30 -29 -28 -27 -26 A -0,16 -0,06 0,10 -0,15 -0,02 -0,03 -0,04 -0,08 0,07 -0,16 -0,03 -0,02 0,05 -0,09 -0,13 C 0,07 0,22 -0,01 0,10 0,12 0,07 0,04 0,06 -0,05 0,11 0,15 0,08 0,19 0,09 0,04 G 0,01 0,09 0,19 0,09 0,20 0,13 0,17 0,05 0,20 0,07 0,12 0,09 0,12 0,04 -0,05 U -0,21 0,01 -0,05 -0,14 -0,08 -0,10 -0,01 -0,15 -0,17 -0,08 -0,20 -0,15 0,03 -0,17 -0,11 -25 -24 -23 -22 -21 -20 -19 -18 -17 -16 -15 -14 -13 -12 -11 A -0,09 -0,12 -0,06 0,06 0,07 -0,01 0,12 -0,07 0,18 -0,10 -0,08 -0,11 -0,09 -0,15 -0,18 C 0,03 -0,01 0,11 0,15 0,08 0,12 -0,11 -0,04 -0,06 -0,11 -0,02 0,04 -0,01 -0,01 0,03 G 0,01 0,01 0,20 -0,08 0,08 0,01 0,00 -0,01 -0,01 -0,02 0,09 0,06 0,05 0,09 0,09 U -0,07 -0,05 0,03 0,04 0,04 0,08 -0,02 0,00 0,03 -0,17 -0,04 0,01 -0,01 -0,02 -0,02 -10 -9 -8 -7 6 7 8 9 10 11 12 13 14 15 16 A -0,23 -0,12 0,00 -0,04 0,07 0,12 0,14 0,11 -0,01 -0,13 -0,17 -0,16 -0,07 -0,04 -0,22 C 0,03 0,09 -0,04 -0,10 0,27 -0,11 -0,20 -0,08 -0,08 0,01 0,05 0,00 0,03 0,03 0,01 G 0,05 -0,01 0,07 0,20 -0,30 -0,04 -0,06 -0,03 0,16 0,18 0,07 0,00 -0,09 -0,07 -0,06 U 0,05 0,03 -0,13 -0,10 -0,20 0,00 0,07 0,04 -0,12 -0,13 -0,05 0,09 0,03 0,03 -0,22 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 A -0,18 -0,19 -0,03 -0,12 0,05 0,05 0,05 0,08 0,00 0,22 0,24 0,09 0,11 0,29 0,49 C 0,05 0,01 -0,03 -0,02 -0,08 -0,07 -0,09 -0,07 -0,04 -0,22 0,06 -0,28 -0,45 -0,27 -0,28 G 0,02 0,08 0,01 0,15 0,04 -0,10 -0,04 -0,03 -0,16 -0,02 -0,03 -0,02 -0,17 -0,12 0,14 U 0,03 -0,16 -0,14 -0,03 -0,04 0,15 0,07 -0,02 -0,09 -0,03 0,22 0,11 0,15 0,22 0,29 32 33 34 35 36 37 38 39
[0114] A 0,25 0,47 0,42 0,09 0,27 0,04 0,15 0,22
[0115] C -0,24 -0,14 -0,07 -0,01 -0,05 -0,12 -0,25 -0,11
[0116] G -0,40 0,14 0,19 0,04 -0,01 -0,15 -0,29 -0,29
[0117] U 0,19 0,18 0,31 0,21 0,23 0,14 0,21 0,11
[0088] Table 2
[0118] -51 -50 -49 -48 -47 -46 -45 -44 -43 -42 -41 -40 -39 -38 -37 A 0,10 -0,09 -0,01 0,01 0,04 -0,09 0,08 0,04 -0,16 -0,11 0,09 0,02 0,09 0,02 -0,08 C 0,12 0,19 0,02 0,08 0,05 0,16 0,07 0,10 0,02 0,05 0,03 0,08 0,10 -0,06 0,22 G 0,05 0,16 0,32 0,29 0,25 0,27 0,20 0,18 0,32 0,29 0,20 0,23 0,22 0,30 0,22 U 0,12 -0,02 -0,03 -0,23 -0,06 -0,24 -0,08 -0,02 -0,01 -0,08 0,01 -0,07 -0,17 -0,04 -0,19 -36 -35 -34 -33 -32 -31 -30 -29 -28 -27 -26 -25 -24 -23 -22 A 0,04 0,02 0,15 -0,06 0,03 0,10 0,13 0,08 0,12 0,02 0,00 -0,12 0,08 -0,05 0,01 C 0,09 0,14 0,09 0,13 0,11 0,19 0,12 0,12 0,13 0,04 0,09 0,17 0,14 0,18 0,14 G 0,27 0,24 0,21 0,24 0,22 0,18 0,15 0,21 0,15 0,26 0,18 0,21 0,15 0,16 0,18 U -0,24 -0,22 -0,20 -0,12 -0,11 -0,29 -0,07 -0,17 -0,10 -0,02 0,00 -0,03 -0,07 -0,05 -0,09 -21 -20 -19 -18 -17 -16 -15 -14 -13 -12 -11 -10 -9 -8 -7 A 0,04 0,06 0,04 -0,10 -0,04 -0,12 -0,08 -0,20 -0,22 -0,14 -0,23 -0,22 -0,09 -0,14 0,10 C 0,17 0,24 0,14 0,11 0,09 0,06 0,13 0,23 0,20 0,15 0,09 0,18 0,25 0,06 0,13 G 0,16 0,08 0,12 0,24 0,28 0,34 0,25 0,15 0,23 0,25 0,34 0,28 0,14 0,26 0,19 U -0,10 -0,05 0,03 -0,02 -0,07 -0,03 -0,07 0,01 -0,05 -0,13 -0,01 -0,01 -0,10 0,08 -0,09 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 A 0,28 0,05 0,13 0,02 -0,03 -0,04 -0,14 -0,09 -0,06 0,04 -0,08 -0,02 -0,13 0,02 -0,02 C 0,38 0,14 0,00 -0,02 -0,04 0,08 0,10 0,14 0,19 0,24 0,19 0,10 0,09 0,12 -0,04 G -0,04 0,21 0,16 0,32 0,41 0,43 0,20 0,07 0,11 0,00 0,13 0,17 0,32 0,21 0,32 U -0,26 -0,13 0,14 -0,05 -0,12 -0,07 0,11 0,34 0,12 0,08 0,11 0,13 -0,14 -0,05 0,14 21 22 23 24 25 26 27 28 29 30 31 32 33
[0119] A 0,16 0,02 0,20 0,11 0,18 0,25 0,15 0,22 0,24 0,12 0,35 0,01 0,22
[0120] C 0,04 0,06 0,06 0,06 0,04 -0,05 0,11 -0,03 0,01 0,13 0,05 -0,06 0,20
[0121] G 0,19 0,19 0,00 0,10 0,09 0,14 0,13 0,08 0,12 0,08 -0,07 0,16 0,11
[0122] U -0,04 0,08 0,13 0,17 0,11 0,08 -0,06 0,21 0,06 0,04 0,19 0,23 -0,30
[0089] Table 3
[0123] -51 -50 -49 -48 -47 -46 -45 -44 -43 -42 -41 -40 -39 -38 -37 A 0,12 -0,07 -0,03 0,07 0,01 -0,09 0,16 0,09 -0,21 -0,11 0,06 0,08 0,11 0,04 -0,02 C 0,15 0,19 0,01 0,11 0,08 0,19 0,12 0,09 0,05 0,04 0,06 0,13 0,12 -0,04 0,21 G 0,05 0,15 0,36 0,25 0,25 0,28 0,13 0,17 0,31 0,29 0,21 0,21 0,19 0,29 0,23 T 0,09 0,02 -0,02 -0,20 -0,07 -0,31 -0,04 0,02 0,03 -0,04 -0,01 -0,11 -0,09 -0,01 -0,23 -36 -35 -34 -33 -32 -31 -30 -29 -28 -27 -26 -25 -24 -23 -22 A 0,15 -0,03 0,18 -0,06 0,08 0,16 0,19 0,12 0,12 0,00 -0,01 -0,12 0,09 -0,13 -0,02 C 0,11 0,15 0,10 0,19 0,18 0,19 0,12 0,17 0,17 0,05 0,09 0,23 0,13 0,20 0,23 G 0,22 0,26 0,17 0,18 0,14 0,16 0,16 0,17 0,10 0,25 0,20 0,19 0,14 0,15 0,10 T -0,24 -0,23 -0,14 -0,07 -0,09 -0,24 -0,09 -0,16 -0,04 0,02 0,02 -0,07 -0,01 0,05 -0,06 -21 -20 -19 -18 -17 -16 -15 -14 -13 -12 -11 -10 -9 -8 -7 A -0,01 0,02 0,06 -0,09 -0,06 -0,17 -0,08 -0,22 -0,31 -0,10 -0,20 -0,19 0,03 -0,05 0,10 C 0,24 0,30 0,14 0,15 0,13 0,08 0,18 0,27 0,26 0,17 0,11 0,25 0,25 0,12 0,23 G 0,10 0,04 0,11 0,18 0,24 0,35 0,22 0,12 0,24 0,23 0,33 0,25 0,06 0,21 0,04 T -0,02 -0,03 0,06 0,03 -0,01 -0,01 -0,07 0,05 -0,03 -0,14 -0,02 -0,10 0,01 0,00 -0,04 -6 -5 -4 -3 -2 -1 4 5 6 7 8 9 10 11 12 A -0,32 0,10 -0,33 -0,93 -0,11 -0,21 0,03 0,12 0,59 0,01 0,10 0,11 0,07 0,01 -0,10 C 0,64 0,11 -0,27 1,55 -0,11 -0,14 1,00 -0,25 0,44 0,29 0,03 0,00 -0,04 0,07 0,08 G -0,27 0,14 0,65 0,03 0,25 0,21 -0,33 0,31 -0,24 0,13 0,08 0,26 0,38 0,44 0,22 T -0,08 -0,38 0,33 2,68 0,44 0,73 -0,09 0,24 -0,29 -0,19 0,26 -0,01 -0,13 -0,09 0,10 13 14 15 16 17 18 19 20 21 22 23 24 25 26 T1 -0,06 -0,08 0,03 -0,06 -0,02 -0,13 0,07 -0,02 0,12 0,04 0,18 0,14 0,23 0,30 0,18 C 0,13 0,23 0,30 0,23 0,10 0,12 0,11 -0,03 0,08 0,10 0,02 0,08 0,06 -0,10 0,11 G 0,05 0,09 -0,07 0,07 0,16 0,32 0,19 0,32 0,16 0,14 0,00 0,07 0,07 0,17 0,12 T 0,38 0,13 0,15 0,16 0,16 -0,17 -0,03 0,16 0,02 0,11 0,20 0,24 0,12 0,09 -0,01 28 29 30 31 32 33
[0124] A 0,24 0,27 0,12 0,37 0,02 0,26
[0125] C -0,05 0,01 0,15 0,07 -0,07 0,22
[0126] G 0,06 0,09 0,04 -0,11 0,16 0,07
[0127] T 0,27 0,09 0,11 0,22 0,25 -0,22
[0128]
[0090] In certain embodiments of the invention, there is provided for a method according to the invention, wherein the sequence of the TIS and TIC in the nucleic acid is modified to ACCACA ATG GC (SEQ ID NO: 1) or, preferably, ACCAAA ATG GC (SEQ ID NO: 2), or wherein the sequence of the TIS and TIC in the modified nucleic acid is ACCACA ATG GC (SEQ ID NO: 1) or, preferably, ACCAAA ATG GC (SEQ ID NO: 2).
[0129]
[0091] In accordance with the method of the invention, the TIC that normally found in eukaryotes, ATG in DNA (coding strand) or AUG in the corresponding RNA / mRNA, may bethe TIC that is included in the nucleic acid or modified nucleic acid according to the invention. However, in some embodiments the TIC may be any suitable TIC in accordance with the invention.
[0130]
[0092] In accordance with the method of the invention, the TIS may be a consensus sequence, in particular, the TIS (or Kozak sequence) is defined per position as: -6 G, -5 C, -4 C, -3 A or G, -2 C, -1 C, +4 G, and +5 G. However, it was surprisingly found that, in accordance with the invention, the TIS sequence may be improved.
[0131]
[0093] Therefore, in certain preferred embodiments, the TIS is defined per position as -6 A, -5 C, -4 C, -3 A, -2 C, -1 A, + 4 G and +5 C or wherein the TIS is defined per position as -6 A, -5 C, -4 C, -3 A, -2 A, -1 A, + 4G, +5 C. In certain preferred embodiments, wherein the TIC is ATG, the TIS and TIC in the modified nucleic acid is modified to ACCACA ATG GC (SEQ ID NO: 1) or, preferably, ACCAAA ATG GC (SEQ ID NO: 2).
[0132]
[0094] It was surprisingly found that, in preferred embodiments, modified nucleic acids that are modified to comprise the above TIS and / or TIS and TIC, may exhibit for improved expression of the protein of interest and / or enhanced translation initiation, and / or decreased expression of alternative proteins initiated at downstream in-frame or out-of-frame alternative TICs.
[0133]
[0095] Therefore, in a preferred embodiment there is provided for a nucleic acid wherein the TIS or TIS and TIC for a protein of interest is as defined above, i.e. in particular wherein the TIS and TIC in the modified nucleic acid is ACCACA ATG GC (SEQ ID NO: 1) or, preferably, ACCAAA ATG GC (SEQ ID NO: 2).
[0134]
[0096] Therefore, in certain embodiments there is also provided is for a plasmid, vector or expression construct, wherein the TIS and TIC for a protein of interest, encoded by a sequence comprised in such plasmid, vector or expression construct is ACCACA ATG GC (SEQ ID NO: 1) or, preferably, ACCAAA ATG GC (SEQ ID NO: 2). As will be understood by the skilled person, the modified nucleic acid may further comprises any other modification as disclosed herein, and in accordance with the invention.
[0135]
[0097] In another embodiment of the method, the nucleic acid is modified to comprise, or wherein the modified nucleic acid comprises one or more of:
[0136] a) a G or T, preferably G, at position +6;
[0137] b) a C or G, preferably C, at position +9;
[0138] c) a A or C, preferably A, at position +12;
[0139] d) a G or C, preferably G, at position +15;
[0140] e) a A or C, preferably A, at position +18;
[0141] f) a C or A, preferably C, at position +21;
[0142] g) a G or C, preferably G, at position +24;h) a T or G, preferably T, as position +27;
[0143] i) a G or C, preferably C, at position +30;
[0144] j) a T or G, preferably T, at position + 33;
[0145] k) a AAA motif at position +16 to +18;
[0146] l) a CCC motif at position +7 to +9;
[0147] m) a CTAAA motif at position +10 to +14;
[0148] n) a AAAAA motif at position -14 to -10
[0149] o) a UUUUUUUUUUU motif at position -37 to -27; and / or
[0150] p) a ATT motif at position -9 to -7;
[0151]
[0098] In an embodiment p) is not CGG.
[0152]
[0099] In certain embodiments, when the one or more modifications are as indicated in k), I) or m) the sequence encoding for a protein of interest may be changed. In certain embodiments, when the sequence encoding for a protein of interest is changed, the resulting expressed protein may or may not contain a change of one or more amino acids. In certain embodiments, the expressed protein does not contain a change of amino acid, for example because the nucleotide modification(s) in the sequence encoding the protein provide for the same amino acid due to the amino acid degenerate code. In other embodiments, when the sequence encoding for a protein of interest is changed, in the resulting expressed protein one or more amino acids are changed, preferably provided that the functionality of the protein is not altered, or, in case of a therapeutic protein, does not cause any adverse effect once translated and expressed in a cell or organism.
[0153]
[0100] In yet another embodiment of the method of the invention, the nucleic acid is modified to comprise, or wherein the modified nucleic acid comprises:
[0154] a) a sequence GAATTTTTAATTTCTTTTATTTTTAAATATTATATAAAAAAAATTACCAAA at positions -51 to -1 (SEQ ID NO: 3);
[0155] b) a sequence TTCTTTTATTTTTAAATATTATATAAAAAAAATTACCAAA at positions -40 to -1 (SEQ ID NO: 4);
[0156] c) a sequence GAATTTTTAATTTCTTTTATTTTTAAATATTATATAAAAAAAATTACCAAAATGNN(G / T)NN(C / G)NN(A / C)NN(G / C)NN(A / C)NN(C / A)NN(G / C)NN(T / G)NN(G / C)NN(T / G) (SEQ ID NO: 5) at positions -51 to +33, wherein a N indicates any one of A, T, C or G.
[0157] d) A sequence at positions -51 to +33 GAATTTTTAATTTCTTTTATTTTTAAATATTATATAAAAAAAATTACCAAAATGGCGCCCTTAA AGAAATACAGGCCTCCGGCT (SEQ ID NO: 6)
[0158]
[0101] In an embodiment, the fragment ACCAAA is not present in any of SEQ ID NO: 3, 4, 5 and 6, which become SEQ ID NOs: 17, 18, 19, and 20, respectively (e.g.GAATTTTTAATTTCTTTTATTTTTAAATATTATATAAAAAAAATT or TTCTTTTATTTTTAAATATTATATAAAAAAAATT).
[0159]
[0102] The following modifications also contribute to an increased translation efficiency and / or protein expression (preferably a statistically significant increased protein expression), preferably at least 1.05-fold, preferably at least 1.1 -fold, more preferably at least 1.2-fold, or more, increase in protein expression compared to the unmodified sequence in a heterologous expression system and / or reduced expression of proteins initiated at downstream in-frame or out-of-frame alternative start codons (TIC), for example wherein translation efficiency is measured by protein yield per mRNA molecule:
[0160] (a) the nucleotide at position +6 is modified compared to the corresponding position in the natural sequence encoding the protein;
[0161] (b) the nucleotide at position -7 is modified as compared to the corresponding position in the natural sequence encoding the protein;
[0162] (c) the nucleotide at position -8 is modified as compared to the corresponding position in the natural sequence encoding the protein;
[0163] (d) the nucleotide at position -9 is modified as compared to the corresponding position in the natural sequence encoding the protein;
[0164] (e) at least one nucleotide at positions -14 to - 11 is modified as compared to the corresponding position in the natural sequence encoding the protein;
[0165] (f) at least one nucleotide at positions -15 to - 12 is modified as compared to the corresponding position in the natural sequence encoding the protein; and / or
[0166] (g) at least one nucleotide at positions +9 to + 13 is modified as compared to the corresponding position in the natural sequence encoding the protein,
[0167] preferably such that the amino acid sequence of the encoded protein is identical to that of the naturally occurring protein.
[0168]
[0103] In certain embodiments,
[0169] (a) the nucleotide at position +6 is modified to a G or U (or corresponding nucleotide when the nucleic acid molecule is DNA), preferably to G;
[0170] (b) the nucleotide at position -7 is modified to not be G, or wherein the nucleotide at position -7 is modified to a C;
[0171] (c) the nucleotide at position -8 is modified to not be G, or wherein the nucleotide at position -8 is modified to a C;
[0172] (d) the nucleotide at position -9 is modified to a G;
[0173] (e) the nucleotides at positions -14 to - 11 are modified to a WWAA motif (wherein W= U or A);(f) the nucleotides at positions -15 to - 12 are modified to a WWAA motif (wherein W= U or A); and / or
[0174] (g) the nucleotides at positions +9 - +13 are modified to not be a AGANT motif (wherein N= A, C, G or U).
[0175]
[0104] In certain embodiments of the invention, the modified nucleic acid comprises a Kozak sequence (within the first and second region as defined) at position -6 - +5, preferably the Kozak sequence being of the form GCCRCCAUGGC (SEQ ID NO: 21) (wherein R is A or G, preferably A).
[0176]
[0105] In certain embodiments of the invention, there is provided for a method of increasing protein expression of a protein-of-interest, the method comprising modifying a nucleic acid as disclosed herein, thereby providing a modified nucleotide, and allowing expression of the protein-of-interest using the modified nucleic acid, thereby allowing increased expression of the protein of interest as compared to the unmodified nucleic acid.
[0177]
[0106] As disclosed herein, the modifications according to the invention are modification introduced into the nucleic acid according to the invention and that thereby may improve expression of the protein of interest, in particular by enhancing translation initiation. Such modifications may be any modification as disclosed herein.
[0178]
[0107] In certain embodiments of the invention, expression of the modified nucleic acid as disclosed herein is achieved by introducing the modified nucleic acid into a suitable host cell. The host cell is preferably a eukaryotic cell, including those disclosed herein. In embodiments the host cell comprises the nucleic acid molecule in accordance with the invention, or comprising a plasmid, vector or expression construct comprising the nucleic acid molecule according to the invention, preferably wherein the host cell is a eukaryotic cells, preferably an animal cell, more preferably a primate cell, a rodent cell, or, most preferably a human cell, and / or wherein preferably the nucleic acid molecule comprises a transgene coding sequence
[0108] In vitro, following expression, the protein of interest may be isolated and purified using standard biochemical techniques. These methods may include cell lysis, centrifugation, filtration, chromatography (such as affinity, ion-exchange, or size-exclusion chromatography), and dialysis. The skilled person can select appropriate purification protocols depending on the nature of the protein, the host system used, and the intended downstream application.
[0179]
[0109] Accordingly, there is provided for a method of increasing protein expression of a protein of interest by modifying a nucleic acid as described herein to produce a modified nucleic acid that exhibits improved translation initiation and / or expression and allowing expression of the protein of interest using this modified nucleic acid, thereby achieving increased protein expression compared to the unmodified nucleic acid.
[0110] In certain embodiments of the invention, there is provided for a method of reducing expression of alternative proteins initiated at downstream of the TIC of the protein-of-interest in-frame out of frame alternative TICs, preferably wherein the alternative TICs are present in the sequence encoding the protein-of interest, the method comprising modifying a nucleic acid as disclosed herein, thereby providing a modified nucleotide, and allowing expression of the protein-of-interest using the modified nucleic acid, thereby favoring translation initiation from the TIC of the protein-of-interest and reducing translation initiation from the alternative TICs.
[0180]
[0111] The skilled person understands that the increased protein expression of the protein of interest, or the reduced expression of alternative proteins as described herein, may also occur in a subject, such as a human or animal, upon administration of the modified nucleic acid according to the invention. For example, upon administrating of the modified nucleic acid, for example DNA, RNA, or mRNA, to the subject by any suitable means, leading to in vivo expression of the protein of interest with improved efficiency and / or reduced off-target protein production. Such administration may be for therapeutic or prophylactic treatment of a subject in need thereof, and the effects observed in the experiments disclosed herein, for example in vitro experiments, with modified nucleic acids according to the invention, are expected to translate to similar improvements in protein expression profiles when administered to a subject, for example a human patient.
[0181]
[0112] Another aspect of the invention relates to a method of increasing protein expression of a protein-of-interest and / or of reducing expression of alternative proteins initiated at inframe or out of frame alternative TICs downstream of the TIC of the protein-of-interest, the method comprising:
[0182] a) identifying the natural sequence of the nucleic acid encoding the protein of interest, and including the TIC, TIS and eTIS;
[0183] b) modifying the natural sequence of the nucleic acid in accordance with the method of modifying the sequence of a nucleic acid as disclosed in any of the aspects and embodiments above, thereby providing a modified nucleic acid; and
[0184] c) optionally, allowing expression of the modified nucleic acid.
[0185]
[0113] The embodiments previously listed to apply to the method of modifying the sequence of a nucleic acid, do also apply to this method of increasing protein expression of a protein-of-interest and / or of reducing expression of alternative proteinsjnitiated at in-frame or out of frame alternative TICs downstream of the TIC of the protein-of-interest.
[0186]
[0114] In certain embodiments of the invention, there is provided for a modified nucleic acid as disclosed herein, for example using the method of the invention as disclosed herein. In preferred embodiments, the nucleic acid according to the invention comprises one or more of the preferred modifications as disclosed herein. As disclosed herein, the modified nucleic acidaccording to the invention is characterized in that it has been modified for improved translation initiation and may this exhibit improved translation efficacy. Consequently, with the modified nucleic acid according to the invention may exhibit improved protein syntheses in comparison to the non-modified nucleic acid. In particular the modified nucleic acid according to the invention may exhibit increased synthesis of the protein of interest and / or may exhibit reduced expression of alternative proteins, as defined herein.
[0187]
[0115] In certain embodiments of the invention, there is provided for a cell, plasmid, expression construct, vector, (m)RNA, vaccine or pharmaceutical composition comprising a modified nucleic acid as disclosed herein.
[0188]
[0116] In certain embodiments of the invention, there is provided for the modified nucleic acid according to the invention as a medicament. In certain embodiments of the invention, there is provided for the modified nucleic acid according to the invention for use in the treatment of a disease in a subject, preferably human subject. In certain preferred embodiments, the disease is selected from viral infections, bacterial infections, cancer, cystic fibrosis, sickle cell disease and beta-thalassemia, Alzheimer’s disease, and / or Parkinson’s disease.
[0189]
[0117] Once introduced, the modified nucleic acid is transcribed and translated within the host cell, resulting in increased expression of the protein of interest compared to the corresponding unmodified nucleic acid. The modified nucleic acid may be present as part of a plasmid, vector, or expression construct, which optionally includes regulatory elements such as promoters, enhancers, and terminators to facilitate efficient transcription and translation.
[0190]
[0118] In certain embodiments of the invention, there is provided for pharmaceutical compositions comprising a modified nucleic acid as disclosed herein, preferably together with one or more pharmaceutically acceptable carriers, excipients, or diluents. The pharmaceutical compositions may be formulated for administration by any suitable route, including but not limited to intravenous, intramuscular, subcutaneous, intradermal, intranasal, oral, or topical delivery. The pharmaceutical compositions may be formulated in unit dosage forms suitable for single or multiple administrations, depending on the therapeutic indication and patient requirements. The dose, frequency, and route of administration can be determined by a physician or skilled person, taking account of factors such as the nature of the disease, the condition of the subject, and the nucleic acid formulation used.
[0191]
[0119] In preferred embodiments, the pharmaceutical composition is administered to a human subject to induce expression of the protein of interest in vivo, thereby providing a therapeutic, or prophylactic effect. The skilled person will recognize suitable dosing regimens to achieve the desired therapeutic effect, preferably while minimizing potential side effects.
[0192]
[0120] Therefore, in certain embodiments of the invention, there is provided for a method of manufacturing a pharmaceutical composition comprising a modified nucleic acid or a protein-of-interest, the method comprising modifying a nucleic acid according to method as disclosed herein, thereby providing a modified nucleic acid, and including the modified nucleic acid, or the protein-of-interest expressed therefrom, in the pharmaceutical composition.
[0193]
[0121] Herewith disclosed is also a method of selecting a modified sequence of a nucleic acid, which is a modified nucleic acid that provides for improved translation initiation efficiency, improved production / expression of the protein of interest, and / or reduction of translation from alternative downstream TICs, as compared to the non-modified nucleic acid sequence, wherein the method comprises:
[0194] a) identifying the sequence of the nucleic acid encoding the protein of interest, and including the TIC, TIS and eTIS;
[0195] b) modifying the sequence of the nucleic acid in accordance with the method of modifying the sequence of a nucleic acid as disclosed in any of the aspects and embodiments above, thereby providing a modified nucleic acid;
[0196] c) allowing expression of the modified nucleic acid; and
[0197] d) determining one or more of translation initiation efficiency, production / expression of the protein of interest, and / or translation from alternative downstream TICs;
[0198] wherein the modified sequence of a nucleic acid is selected as candidate for the production / expression of the protein of interest if translation initiation efficiency, and / or production / expression of the protein of interest is / are higher compared to the unmodified nucleic acid and / or if translation from alternative downstream TICs is reduced relative to the unmodified nucleic acid.
[0199]
[0122] Non-limiting, methods for the determining of any of the translation initiation efficiency, the production / expression of the protein of interest, and / or the translation from alternative downstream TICs are known to the skilled person, and include those disclosed herein.
[0200]
[0123] Directly deducible from this method of selecting an (improved) modified nucleic acid sequence is that with the obtained (selected) sequence leaky scanning by the ribosome is reduced, minimized or totally avoided. This is of importance, for example, for vaccines based on nucleic acids, such as mRNA vaccines, where it is desired a high expression of the epitope of interest instead of any variation that could occasion adverse effects or no effects, for example.
[0201]
[0124] Finally, there is provided for a method of a computational-implemented algorithm for training a deep convolutional neural network (DCNN) to predict translation-initiation activity as disclosed herein, and for the use of a computer-implemented method for predicting translationinitiation activity as disclosed herein.
[0202]
[0125] It was found that the combination of Massively Parallel Reporter Assays (MPRAs) and deep learning, particularly deep convolutional neural networks (DCNNs), offers a powerfulsolution for predicting translation-initiation efficacy (or activeity). MPRAs can be adapted to test 5'UTR variants in parallel, providing direct measurements of translation initiation and the influence of sequence context on this process. DCNNs, in turn, can learn from this data to capture complex patterns and predict the effect of new sequences, including variants not directly measured in experiments. The DCNN model is trained on MPRA data, where each sequence is associated with a measurement of translation initiation activity. During training, each RNA sequence is fed into the DCNN model, which then predicts a value. This predicted value closely matches the measured translation initiation activity. This is ensured by a loss function, that minimizes the error between the predictions and the measurements. Once this process is performed for all sequences in the MPRA dataset, training is complete. The trained DCNN model can then be used to predict translation initiation levels for sequences outside the training set. The training and predicting procedures used are the standard in machine learning, and the skilled person understand how to use and imply these.
[0203]
[0126] In particular, the DCNN model may be trained using highly accurate measures of translation initiation of a sequence of interest assessable in a high-throughput manner; optionally a wide range of natural and / or synthetic 5'UTRs and part of the coding sequence (CDS), possibly with varying Kozak motifs, for example so that the initial pool is diverse enough / provide a broad range of expression levels; optinally variants that challenge the model, including random mutations and rare or divergent sequences and / or redundant overlapping fragments to reduce experimental noise and improve signal robustness.
[0204]
[0127] Further, a subset of RNA sequences may be withheld from training to serve as the validation set for model evaluation. As will be understood by the skilled person, potentially multiple rounds of model optimization can be performed to improve the performance. For example, the sequences generated in earlier iterations of the model, either synthetic sequences or sequences for which the predictions are highly unstable, are subsequently measured and used as input to update and improve the model.
[0205]
[0128] Therefore, there is provided for a computational-implemented method or algorithm for training a deep convolutional neural network (DCNN) to predict translation-initiation activity of a nucleic acid sequence, preferably including positions -100 to + 50 (as defined herein), more preferably -90 to + 40 (as defined herein), even more preferably -51 to + 40 (as defined herein), or part thereof of at least 15 nucleotides, preferably at least 20 nucleotides, preferably including a TIC. In further embodiments, the sequence includes positions -80 to +80 (as defined herein), -51 to + 40 (as defined herein), -40 to + 40 (as defined herein), or part thereof of at least 15 nucleotides, preferably at least 20 nucleotides, preferably including a TIC. The method or algorithm comprising, by one or more processors:1 ) receiving, from a memory, a dataset comprising a plurality of nucleic acid sequence measurement records, each associating a measured translationinitiation activity value obtained from a massively parallel reporter assay (MPRA); 2) preprocessing the plurality of nucleic acid sequences to generate digital sequence representations suitable for neural network input;
[0206] 3) training the DCNN using the digital sequence representations as inputs and the measured translation-initiation activity values as supervised targets, wherein the DCNN learns to map sequence context to translation-initiation activity by optimizing a loss function that quantifies prediction error; and
[0207] 4) storing the trained DCNN model parameters in a non-transitory computer-readable storage medium.
[0208]
[0129] The nucleic acid sequence in the computational-implemented method or algorithm according to the invention may be any sequence, preferably any sequence comprising a TIC, as defined herein. Preferably, the sequence includes positions -100 to + 50 (as defined herein), more preferably -90 to + 40 (as defined herein), even more preferably -51 to + 40 (as defined herein), or part thereof of at least 15 nucleotides, preferably at least 20 nucleotides, preferably including a TIC. In further embodiments, the sequence includes positions -80 to +80 (as defined herein), -51 to + 40 (as defined herein), -40 to + 40 (as defined herein), or part thereof of at least 15 nucleotides, preferably at least 20 nucleotides, preferably including a TIC For example, the nucleic acid sequence may comprise position -15 to -1, or -15 to + 6, and any other sequence of at least 15 nucleotides, preferably at least 20 nucleotides upstream or downstream of the TIC. The training is completed once that all the nucleic acid sequences are fed into the model.
[0209]
[0130] Also provided is for the use of a trained DCNN model for predicting translation-initiation activity of a nucleic acid sequence. In particular there is provided for a computer-implemented method for predicting translation-initiation activity of a nucleic acid sequence, preferably including positions -100 to + 50 (as defined herein), more preferably -90 to + 40 (as defined herein), even more preferably -51 to + 40 (as defined herein), or part thereof of at least 15 nucleotides, preferably at least 20 nucleotides, preferably including a TIC. In further embodiments, the sequence includes positions -80 to +80 (as defined herein), -51 to + 40 (as defined herein), -40 to + 40 (as defined herein), or part thereof of at least 15 nucleotides, preferably at least 20 nucleotides, preferably including a TIC. The method comprising, by one or more processors:
[0210] 1) receiving a trained deep convolutional neural network (DCNN) model previously trained to map sequence context to translation-initiation activity, preferably the DCNN model obtained according to the method for training as disclosed herein;
[0211] 2) receiving one or more query nucleic acid sequences, preferably not present in the training dataset;3) optionally, preprocessing the query sequences to generate digital sequence representations suitable for input to the trained DCNN;
[0212] 4) applying the trained DCNN to the one or more query nucleic acid sequences or digital representations to generate predicted translation-initiation activity values for the query sequences;
[0213] 5) optionally identifying one or more regulatory sequence motifs contributing to translation-initiation activity by analysing the trained DCNN using a model-interpretation technique;
[0214] 6) outputting the predicted translation-initiation activity values and, optionally, the identified regulatory motifs.
[0215]
[0131] The query nucleic acid sequence, e.g. for which translation-initiation activity (or efficacy) is to be predicted, may be any sequence, preferably any sequence comprising a TIC, as defined herein. Preferably, the sequence includes positions -100 to + 50 (as defined herein), more preferably -90 to + 40 (as defined herein), even more preferably -51 to + 40 (as defined herein), or part thereof of at least 15 nucleotides, preferably at least 20 nucleotides, preferably including a TIC. For example, the nucleic acid sequence may comprise position -15 to -1, or -15 to + 6, and any other sequence of at least 15 nucleotides, preferably at least 20 nucleotides upstream or downstream of the TIC. In further embodiments, the the sequence includes positions -80 to +80 (as defined herein), -51 to + 40 (as defined herein), -40 to + 40 (as defined herein), or part thereof of at least 15 nucleotides, preferably at least 20 nucleotides, preferably including a TIC.
[0216]
[0132] The computer-implemented method disclosed herein may also be used as or in a method for a method of sequence optimization with in silico evolution Starting from an initial set of sequences (either naturally occurring or randomized), the algorithm introduces mutations or recombines sequences while preserving the encoded protein sequence. The translation initiation score is then calculated for all the sequences, and only those showing improved translation initiation are retained for the next round. In subsequent rounds, the retained sequences are further mutated and recombined, with the highest-scoring sequences selected each time. This iterative process continues for several rounds until the predictions reach a plateau. After the final round of evolution, the evolved sequences with the most improved translation initiation score are provided as output. The improved translation initiation efficiencies of the evolved sequences can experimentally be validated.
[0217]
[0133] The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying knowledge within the skill of the art (including the contents of the references cited herein), readily modify and / or adapt for various applications such specific embodiments, without undue experimentation, without departing from the general concept of the present invention. Therefore, such adaptations andmodifications are intended to be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein.
[0218]
[0134] All references cited herein, including journal articles or abstracts, published or corresponding patent applications, patents, or any other references, are entirely incorporated by reference herein, including all data, tables, figures, and text presented in the cited references. Additionally, the entire contents of the references cited within the references cited herein are also entirely incorporated by references.
[0219]
[0135] It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance presented herein, in combination with the knowledge of one of ordinary skill in the art.
[0220]
[0136] It will be understood that all details, embodiments, and preferences discussed with respect to one aspect of embodiment of the invention is likewise applicable to any other aspect or embodiment of the invention and that there is therefore not need to detail all such details, embodiments, and preferences for all aspect separately.
[0221]
[0137] Having now generally described the invention, the same will be more readily understood through reference to the following examples which is provided by way of illustration and is not intended to be limiting of the present invention. Further aspects and embodiments will be apparent to those skilled in the art.
[0222] EXAMPLES
[0223] Example 1
[0224]
[0138] Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation.
[0225]
[0139] Reference to known method steps, conventional methods steps, known methods or conventional methods is not in any way an admission that any aspect, description, or embodiment of the present invention is disclosed, taught, or suggested in the relevant art. Methods
[0226]
[0140] Cell lines: HEK293T and HeLa cells were cultured in DMEM (GIBCO) supplemented with 5% FCS (Sigma-Aldrich) and 1% PenStrep (GIBCO). Cells were cultured at 37°C and 5% CO2. Cell lines used in this study were routinely tested for presence of mycoplasma.
[0227]
[0141] Plasmid construction: The RiboScan reporter (as exemplified in Figure 4A, 4B), is a lentiviral plasmid system that expresses two fluorescent proteins each representing the translation of one open reading frame (ORF). The mCherry fluorophore reports on start codonrecognition of the main start codon. The GFP fluorophore reports on leaky scanning ribosomes, which failed to recognize the main start codon, and its sequence is encoded in the +1 frame. The synthesis of GFP is initiated on an AUG start codon in strong sequence context (Kozak consensus sequence; GCCACCAUGGC (SEQ ID NO 7) that is part of the reporter sequence. We precisely inserted the 5’UTR sequence of hundreds of human genes together with nucleotides of the coding sequence of human transcripts or therapeutic mRNA sequences directly downstream of the transcription start site (TSS) of the CMV-promoter and before the RiboScan reporter via large scale library cloning. The introduced sequences either matched the endogenous sequence of the human mRNAs or modified versions (exemplary genes used where: CALR, ENST00000316448.10; DBI, ENST00000355857.8: ILF2, ENST00000361891.9; MAGOH, ENST00000371470.8; MT2A, ENST00000245185.6; NDUFB1, ENST00000605997.6 ;NUCB1, ENST00000405315.9; PSMD6, ENST00000295901.9; RAN, ENST00000543796.6; RPLP2,ENST00000321153.9;SARS1.ENST00000234677.7;
[0228] SH3BGRL3,ENST00000270792.10; SRM,ENST00000376957.7; TOMM7, ENST00000358435.9; all references according to Ensembl Transcript ID (Ensembl Version 110, July 2023), in which either all point mutations were introduced in the region -40 to +33 and the TIS was changed to TTATTGATGGG (SEQ ID NO 8), CCCAGTATGCG (SEQ ID NO 9) or CCACTTATGAC (SEQ ID NO 10) or only the endogenous translation initiation sequence (TIS) was changed to TTATTGATGGG (SEQ ID NO 8) or CTTTCGATGTC (SEQ ID NO 11 ) (in 1000 transcripts the TIS was changed). For several (more than 70) endogenous human mRNA sequences the TIC was changed from AUG to C / GUG and / or the extended translation initiation sequence (eTIS) was optimized according to the method of the invention). Finally, individual segments of the eTIS were optimized separately, or the entire eTIS was optimized as a whole, to determine whether the cumulative effect of optimizing individual fragments differs from that of full eTIS optimization.
[0229]
[0142] In addition to the RiboScan reporter, a second plasmid was constructed in which GFP expression directly reflects TIC recognition. Sequences derived from therapeutic mRNAs were introduced into this reporter system. To ensure that the GFP expression levels was not affected by the protein stability of the introduced mRNA sequence, the coding sequence of the therapeutic mRNAs was separated from GFP using a T2A self-cleaving peptide. In addition, sequences in which the eTIS of the therapeutic mRNAs was optimized were introduced.
[0230]
[0143] Library design: mRNA sequences were obtained from Ensembl (Release V108, October 2022). All transcripts with a Refseq ID and a UTR length between 30 and 95 nucleotides were considered as input for the libraries and a subset of these transcripts were randomly sampled. The complete 5’UTR and the first 18 nucleotides of the CDS of thetranscripts were downloaded using BiomaRt. A selection of transcripts was selected for investigation, randomly. In case multiple transcript isoforms were selected per gene, each of the transcripts was uniquely labeled by adding a unique number to the gene name (indicated as Gene_name. Number in the library). SNP information was obtained from the International Cancer Genomics Consortium (simple_somatic_mutation. aggregated. vcf, downloaded on 22-12-2022) and the “Human Somatic Short Variants" dataset from Ensembl (Release 108, October 2022) for the same transcripts. Of several transcripts, all mutations in the 5’UTR and the first 18 nucleotides of the CDS were included as separate elements in the library. Transcripts encoding tumor suppressor genes or proto-oncogenes were prioritized. The remaining transcripts for which SNPs were studied were picked randomly. Sublibraries were created by UTR length and experiment type and equipped with a unique sequence for library specific PCR amplification.
[0231]
[0144] Library cloning: Libraries were cloned using a modified protocol (not shown). Libraries were PCR amplified from the synthesized oligopool (Twist Bioscience) with Q5 DNA polymerase (NEB) according to the instructions provided by the manufacture. The PCR products were cleaned using gel electrophoresis (GeneJET gel extraction kit, Thermo Scientific) and digested with PaqCI (Aarl, NEB) and EtOH precipitated. The RiboScan reporter plasmid was digested with PaqCI and cleaned using gel electrophoresis (GeneJET gel extraction kit, Thermo Scientific). Elements were ligated in the reporter plasmid with T4 DNA ligase (NEB) with a molar ratio of 1:2 backbone over insert, for 16 hours at 16”C. Ligated plasmids were EtOH precipitated and per library a test transformation was performed with DH5a bacteria as well as a transformation with the digested backbone to check for digestion efficiency. Single colonies were inoculated and sequenced for verification of library integration and used for quality control assessments later on. Large-scale transformations were performed with MegaX DH10B electro competent cells as described in
[0066] .
[0232]
[0145] Lentiviral transduction: The various libraries were introduced into cells using lentiviral infection. For this, pHR-based lentiviral plasmids containing the various RiboScan libraries were transfected into HEK293T cells together with pMD2G and psPAX2 helper plasmids using PEI (Polyethylenimine, Polysciences Inc.). After one day the medium was refreshed. After 4 days, virus-containing supernatant was passaged over a 0.33pm filter to remove cellular debris and stored at -20°C. The virus-containing supernatant was added to HEK293T cells, and the cells were placed back in the incubator. Six hours after virus addition the cells were washed once with PBS and fresh medium was added. 48 hours after transduction medium was refreshed with medium containing puromycin (1:10.000, 10mg / mL ThermoFisher). A fraction of the cells were kept aside for MOI determination. At most 10% of cells should be infected, to ensure a low amount of double infected cells. The integration site of the lentivirus affects theexpression levels. To control for expression noise, we therefore made sure that the average coverage of each sequence element amounted at least 100x after infection. After at least one week of puromycin selection cells were sorted by FACS.
[0233]
[0146] FACS: Cells were grown to a confluency of 70%, washed twice with PBS and dissociated with trypsin. Cells were prepared for FACS sorting by resuspension in 1xPBS with 10% FCS. All FACS sorts were carried out using BD FACS Fusion using a GFP and mCherry laser (488nm excitation laser with a 530nm emission filter and 532nm laser with a 610 / 620 emission filter, respectively). Cells transduced with the lentiviral libraries were sorted based on the GFP / mCherry ratio. Cell lines expressing one reporter element were used to set the correct gating. Gates were set with equal spacing and the same amount of cells were sorted per gate. The coverage of each library element was approximately 400 times. To obtain the coverage of each gate we acquired a preliminary recording of the sample prior to the FACS sort. Cells were collected in 2mL Eppendorf tubes and pelleted directly after sort by centrifugation at 1200 rpm for 5 min at 4°C, the supernatant was removed, and the samples were stored at -20°C until library preparation within 48 hours. Two biological repeats were sorted per experiment.
[0234]
[0147] Barcoding and library preparation: The elements from each sorted FACS gate were PCR amplified, barcoded and sequenced. Genomic DNA from the cells was extracted using a genomic DNA extraction kit (GeneJET gDNA extraction kit, ThermoFisher). PCR amplification was performed with a high fidelity DNA polymerase (Q5, NEB) in the presence of high GC-buffer for 20 to 25 cycles. The reverse primer (5’-GTGACTGGAGTTCCTTGGCACCCGAGAATTCCANNNNNNNNGTGCCCGTTGACGTCGC-3’; (SEQ ID NO 12)) contains an eight nucleotide long index corresponding to the FACS gate. The forward primer is complementarity to the end of the CMV promoter (5’-TTCAGAGTTCTACAGTCCGACGATCGCAGAGCTGGTTTAGTGAAC-3’; (SEQ ID NO 13)). PCR products were purified from gel (GeneJET gel extraction kit, ThermoFisher), measured using a Qubit high sensitivity dsDNA assay (ThermoFisher), and pooled in equal molecular ratio. TruSeq small RNA primers (Illumina) were used for the preparation of the Illumina sequencing libraries in a final PCR reaction ran for eight cycles. Each individual repeat of each library in a sequencing run was equipped with a unique TruSeq index. Sequencing libraries were run on an Illumina NextSeq2000 platform (high output 2x100bp) or an Illumina NextSeq500 platform (Mid output 2x150bp).
[0235]
[0148] Read processing: Sequencing reads were trimmed using CutAdapt (version 3.5) . For the lentiviral libraries the adapters 5’-GCAGAGCTGGTTTAGTGAACC-3’ (SEQ ID NO 14), matching the CMV promoter, and 5’-GGCGGCAGCGGCTCAGGAA-3’ (SEQ ID NO 15), matching the GS-linker of the RiboScan reporter were removed from read one to obtain thefull library element. Untrimmed reads were removed. The FACS-seq gate IDs were obtained by taking the first eight bases from read two.
[0236]
[0149] Calculating a GFP intensity for each library element: The processed reads were parsed through a custom script to assign a GFP intensity to each library element. All trimmed read pairs of a library were filtered and grouped by the presence of a correct gate ID. Read pairs without a correct gate ID and a forward read which sequence fully matched a sequence from the library were excluded from further analysis. The sequences were first normalized by gate ID reads, such that each gate ID represented an equal fraction of the total population of reads. Subsequently, read normalization was performed per library element such that the sum of all sequencing reads per library element across all gates is equal to one. Since the expression range of each library element over the FACS-gates should be limited to a few FACS-gates, we performed peak-calling using a custom peak calling algorithm. Shortly, the algorithm identified a region of three or four consecutive gates in which the fraction of sequencing reads spike. The read fraction of gates outside the defined peak were set to zero and read normalization was repeated on the remaining gates, such that the sum of all remaining sequencing reads per library element is equal to one. Finally, the fractions of sequencing reads in each FACS-seq gate were multiplied with the median GFP intensity of each FACS-gate and summed to obtain a final GFP intensity per library element. Library elements with less than 50 reads were excluded from further analysis. A mean GFP intensity was calculated by calculating the average GFP intensity over the two independent biological repeats.
[0237]
[0150] Determining fraction of ribosomes undergoing alternative translation: The bicistronic reporters that express BFP and either the GFP or the mCherry in the same configuration as in the RiboScan reporter can be used to convert the GFP signal into a fraction of leaky scanning ribosomes within the total pool of ribosomes on each library element. By measuring the GFP-to-BFP and mCherry-to-BFP ratios, we can calculate the correlation between mCherry and GFP signals through linear regression analysis, resulting in the following relationship:
[0238]
[0151] loglO(GFP) = 0.56 + 1.065 • log 10 (mCherry)
[0239]
[0152] Since GFP can now be expressed as a function of mCherry, the total fraction of ribosomes undergoing leaky scanning can be represented as follows:
[0240]
[0153] Fraction leaky scanning ribosomes —
[0241] measured GFP levels (expressed as mCherry)
[0242] total signal (measured mCherry levels+measured GFP levels measured (as mCherry
[0243]
[0154] Several cell lines were developed, each containing a single library element introduced through lentiviral transduction. FACS analysis was conducted on these cell lines individually to measure GFP and mCherry expression levels accurately. These measurements were then used to obtain an average total signal. Finally, this average total signal was used to calculatethe fraction of leaky scanning ribosomes for each library element by dividing the GFP values obtained for each library element after FACS-seq by the average total signal.
[0244]
[0155] Data analysis: After calculating the GFP expression values and initial filtering the data was further processed. A custom script was used to assign the introduction or removal of (nearcognate) start codons and stop codons upon mutating distal sequences, as well as the introduction or the loss of uORFs in each sequence variant. The wild-type sequences were used as a reference. Sequence variants in which such sequence elements introduced were removed from further analysis, unless specifically investigated. Unless stated otherwise, the average GFP intensity of the two repeats is plotted in the graphs. For each library element the mean free energy (MFE) was determined using RNAfold of the Vienna RNA package. Differential expression analysis was performed using Limma. Mutations that caused a fold change above 1.25 and an adjusted p-value (BH procedure) below 0.05 were considered mutations that cause a significant change in start codon recognition.
[0245]
[0156] Translation frame analysis of downstream AUG: To determine whether the enhanced efficiency of start codon recognition upon the introduction of foreign TISes is correlated with the presence of a downstream in-frame AUG we performed translation frame analysis. To identify transcripts on which the introduction of foreign TISes had a positive effect on start codon recognition the following criteria were used: either the average logs fold change of the three foreign TISes and the native TIS of the gene should be less than -1 , or for two out of the three foreign TISes the Iog2 fold change with the native TIS of the gene should be less than -1. The same criteria where used for the selection of transcripts that experienced enhanced leaky scanning upon the introduction of foreign TISes. For these transcripts the average Iog2 fold change between the three foreign TISes and the native TIS of the gene should be more than one or for two out of the three foreign TISes the Iog2 fold change with the native TIS of the gene should be more than 1. The distributions of the reading frames (-1 ,0,+1 ) were plotted and as a control the distribution of all first downstream AUGs in the transcriptome were taken (Ensembl canonical transcripts, Ensembl Release 110, July 2023)
[0246]
[0157] Ribosomal profiling data: Pre-analyzed ribosomal profiling datasets of initiating ribosomes in HEK293T cells were downloaded from https: / / gwips.ucc.ie / cgi-bin / hgGateway. Reads mapped to the genomic regions of interest were aligned and summed to create coverage plots over the mRNA transcripts.
[0247]
[0158] Motif discovery: The mutations that caused a significant change in start codon recognition were grouped by start codon recognition enhancing or reducing mutations. The mutation tiles were extended with maximal 2 nucleotides at both sides of the mutation tile to allow the inclusion of motifs that are partly overlapping different tiles. Tiles that include TIS bases were excluded from motif discovery. Differential enrichment analysis was performedwith STREME of the MEME suite, using the two groups as input sequences and the sequences that did not cause a significant change in start codon recognition as control sequences. All motifs with an E-value smaller than 0.05 were inspected for local enrichment.
[0248]
[0159] Transcriptome-wide enrichment of +6 nucleotide: To study the enrichment of nucleotides at the +6 position in the transcriptome the complete transcriptome was downloaded from Ensembl using BiomaRt. Yeast 5’UTR sequences were derived from mRNA sequencing data obtained from Pelechano et al. Transcripts were filtered on the following criteria; Transcripts are filtered on transcript biotype, transcripts should be protein coding. To weigh the contribution of each gene equally, only the Ensembl canonical transcripts were considered. The canonical transcript for each gene is assigned by Ensembl. Canonical transcripts are the most conserved, the highest expressed and are represented in other resources such as NCBL Finally, transcripts should have a minimal 5’UTR length of six nucleotides in order to assign a TIS strength.
[0249]
[0160] The average nucleotide frequency of all third codon bases over all annotated protein coding ORFs was calculated. This global nucleotide frequency was used as a reference to calculate nucleotide enrichment at specific codons positions. Subsequently, the local nucleotide frequency at the 3rdbase of each individual codon position was calculated over all annotated protein coding ORFs. Local nucleotide enrichment was calculated by subtracting the global nucleotide frequency from the local nucleotide frequency for all four nucleotides. A similar approach was used to obtain nucleotide enrichment per codon set. Instead of calculating a global nucleotide frequency for all codons simultaneously, codons were first grouped by the nucleotide composition at base one and two and the encoded amino acid, after which for each codon set a global nucleotide frequency was calculated. For each individual codon position codons were similarly grouped and per codon set and codon position a local nucleotide frequency was calculated. The nucleotide enrichment was obtained by subtracting the global nucleotide frequency per codon set across all positions from the local nucleotide frequency per codon set. Finally, nucleotide enrichment at the +6 position were calculated by subtracting the average nucleotide enrichment of positions +9, +12 and +15 from the nucleotide enrichment at position +6.
[0250]
[0161] TSS-T / S plots: For all investigated organisms for each transcript the genomic coordinate of the transcription start sites as well as the genomic coordinate of the start codon (the G of the AUG) was obtained from Ensembl. Genomic sequences were downloaded centered around these reference points. For the TIS trace only every third nucleotide was used (..,-13, -10, -7, +6, +9, +12,..), the G of the AUG and the Kozak bases were excluded given the strong preference for specific nucleotides at these positions. For each genomic position, the nucleotide frequency was obtained. Transcripts were either grouped by 5’UTR length or bygenomic distance between the TSS and the start codon. For the TSS-TIS plot the data was split into two parts. The first part contains the data that was centered around the TSS. All nucleotides from a selected point upstream to either halfway the 5’UTR or to halfway the genomic distance between the TSS and the start codon are used for this fraction of the plot. The second part of the plot contains the information that is centered around the start codon, starting at either halfway the 5’UTR or halfway the genomic distance between the TSS and the start codon to a selected number of nucleotides downstream of the TSS.
[0251]
[0162] Nucleotide enrichment and 5’UTR length: To study nucleotide enrichment at the +6 position over 5’UTR length, transcripts were first grouped by 5’UTR length. To increase the number of transcripts per 5’UTR length, transcripts were grouped by intervals of five nucleotides. 5’UTRs groups with less than 50 transcripts were excluded from the analysis. Subsequently, the nucleotide frequencies at the +6 position were calculated and the global nucleotide frequencies was subtracted. For comparison, similar analysis were performed for the nucleotides at the +9 and the +12 position.
[0252]
[0163] Nucleotide enrichment and TIS strength: The nucleotide frequency at the +6 position across all transcripts was calculated and plotted against TIS strength. Genetic information of uORFs for which translation was validated were obtained from. To obtain the +6 nucleotide frequencies of o- and uORFs of which translation has not been validated a custom script was used to identity all upstream and overlapping ORFs in all transcripts. Validated translated o-uORFs from were removed from the dataset by filtering on genomic coordinates.
[0253]
[0164] Upstream nucleotide enrichment: Nucleotide frequencies were calculated for each position in the mRNAs ranging from positions -60 or -40 to -7 in the mRNAs. For dinucleotide enrichment analysis, the dinucleotide frequencies were obtained by dividing the transcripts into 28 non-overlapping dinucleotides from position -60 to position -7. Transcripts with a 5’UTR length shorter than 60 nucleotides were excluded from the analysis. To obtain dinucleotide enrichment, the average of the frequencies at the three upstream dinucleotides were subtracted from the dinucleotide frequencies at position -8,-7. The same strategy was applied to obtain the trinucleotide enrichments at positions -9 to -7 and -12 to -10.
[0254]
[0165] Determining optimal eTIS sequences: To generate the data presented in Table 1 in this description, the following analysis was performed. For the single nucleotide substitution analysis, the mean GFP intensity associated with each nucleotide (A, C, G, or U) at every position within the eTIS region was calculated. A log2fold change (log2FC) was then computed relative to the average GFP intensity of the corresponding gene. Subsequently, the average log2FC for each nucleotide at each position was calculated across all genes. A negative log2FC indicates that the presence of a specific nucleotide at a given position enhances start codon recognition, resulting in reduced mean GFP expression and less leaky scanning. In contrast,a positive log2FC suggests impaired start codon recognition, leading to increased mean GFP expression and more leaky scanning.
[0255]
[0166] To generate the data presented in Table 2 and 3 in this description the following analysis was conducted. For all genes in which the same TIS was introduced, the data were grouped based on nucleotide identity at each position within the sequence. For each nucleotide (A, C, G, or U) at each position, the average GFP intensity was calculated. A log2fold change was then determined by comparing the mean GFP intensity for each nucleotide to the overall mean intensity across all genes.
[0256]
[0167] An optimal eTIS can be achieved by introducing, at each nucleotide position, the nucleotide associated with the lowest log2fold change in mean GFP expression.
[0257]
[0168] Next Table 4 includes the sequences disclosed in this text and provided in the sequence listing that forms part of this description.
[0258] Table 4. Sequences
[0259] SEQ ID Nucleic acid sequence (NA) molecules (5'to 3')
[0260] NO:
[0261] 1 ACCACA ATG GC
[0262] 2 ACCAAA ATG GC
[0263] 3 GAA I 1 1 1 1 AATTTCTTTTA 1 1 1 1 1 AAATATTATATAAAAAAAATTACCAAA
[0264] 4 TTCTTTTA 1 1 1 1 1 AAATATTATATAAAAAAAATTACCAAA
[0265] 5 GAA I 1 1 1 1 AATTTCTTTTA 1 1 1 1 1 AAATATTATATAAAAAAAATTACCAAAATGNN(G / T)NN(C / G)NN(A / C)NN(G / C)NN(A / C)NN(C / A)NN(G / C)NN(T / G)NN(G / C)NN(T / G)
[0266] Represented in the sequence listing as
[0267] GAAI 1 1 1 IAA I 1 I C I 1 1 IAI 1 1 1 1 AAATATTATATAAAAAAAATTACCAAAATGNNKNNSNNM NNSNNMNNMNNSNNKNNSNNK, which is according to the IUPAC-IUB ambiguity codes
[0268] 6 GAA I 1 1 1 1 AATTTCTTTTA 1 1 1 1 1 AAATATTATATAAAAAAAATTACCAAAATGGCGCCCTTAAA GAAATACAGGCCTCCGGCT
[0269] 7 GCCACCAUGGC (Kozac sequence), represented in the sequence listing with a T at position 8 of the codingDNA; GCCACCATGGC.
[0270] 8 TTATTGATGGG
[0271] 9 CCCAGTATGCG
[0272] 10 CCACTTATGAC
[0273]
[0274] 11 CTTTCGATGTCSEQ ID Nucleic acid sequence (NA) molecules (5'to 3')
[0275] NO:
[0276] 12 GTGACTGGAGTTCCTTGGCACCCGAGAATTCCANNNNNNNNGTGCCCGTTGACGTCGC (reverse primer)
[0277] 13 TTCAGAGTTCTACAGTCCGACGATCGCAGAGCTGGTTTAGTGAAC (forward primer) 14 GCAGAGCTGGTTTAGTGAACC adapter
[0278] 15 GGCGGCAGCGGCTCAGGAA adapter
[0279] 16 motif UUU UUU UUU UU , represented in the sequence listing as TTT TTT TTT TT
[0280] 17 (SEQ ID NO: 3 with the fragment ACCAAA removed)
[0281] GAA 1 1 1 1 1 AA 1 1 1 C 1 1 1 1 A 1 1 1 1 1 AAATATTATATAAAAAAAATT
[0282] 18 (SEQ ID NO: 4 with the fragment ACCAAA removed)
[0283] TTCTTTTATTTTTAAATATTATATAAAAAAAATT
[0284] 19 (SEQ ID NO: 5 with the fragment ACCAAA removed)
[0285] GAAI 1 1 1 IAA I 1 I C I 1 1 IAI 1 1 1 1 AAATATTATATAAAAAAAATTATGNN(G / T)NN(C / G)NN(A / C)NN(G / C)NN(A / C)NN(C / A)NN(G / C)NN(T / G)NN(G / C)NN(T / G)
[0286] Represented in the sequence listing as
[0287] GAA I 1 1 1 IAA I 1 I C I 1 1 IA I 1 1 1 IAAATATTATATAAAAAAAATTATGNNKNNSNNMNNSNNM NNMNNSNNKNNSNNK, which is according to the IUPAC-IUB ambiguity codes
[0288] 20 (SEQ ID NO: 6 with the fragment ACCAAA removed)
[0289] GAA 1 1 1 1 1 AA 1 1 1 C 1 1 1 1 A 1 1 1 1 1 AAATATTATATAAAAAAAATTATGGCGCCCTTAAAGAAATA CAGGCCTCCGGCT
[0290] 21 GCCRCCAUGGC, wherein R is A or G, - variability in Kozac sequence, represented in the sequence listing with a T at position 8 of the coding DNA; GCCRCCATGGC 22 AAUUAUAUGAU represented in sequence listing as AATTATATGAT
[0291] 23 UACCUUAUGAU represented in the sequence listing as TACCTTATGAT
[0292] 24 UUGCUUAUGGA represented in the sequence listing as TTGCTTATGGA
[0293] 25 GGAAAAAUGCG represented in the sequence listing as GGAAAAATGCG
[0294] 26 GUUGCAAUGCU represented in the sequence listing as GTTGCAATGCT
[0295] 27 AAGACCAUGGG represented in the sequence listing as AAGACCATGGG
[0296] 28 CCAGCCAUGCU represented in the sequence listing as CCAGCCATGCT
[0297] 29 CGGAACAUGUU represented in the sequence listing as CGGAACATGTT
[0298] 30 GAUAAGAUGAU represented in the sequence listing as GATAAGATGAT
[0299] 31 ACGGGCAUGCU represented in the sequence listing as ACGGGCATGCT
[0300] 32 AGCGUGAUGCG represented in the sequence listing as AGCGTGATGCG
[0301] 33 CUGCAAAUGUG represented in the sequence listing as CTGCAAATGTG
[0302] 34 GACCACAUGUU represented in the sequence listing as GACCACATGTT
[0303]
[0304] 35 CCACUUAUGAC represented in the sequence listing as CCACTTATGACSEQ ID Nucleic acid sequence (NA) molecules (5’to 3’)
[0305] NO:
[0306] 36 GGAAAAAUGCG represented in the sequence listing as GGAAAAATGCG
[0307] 37 CUUUCGAUGUC represented in the sequence listing as CTTTCGATGTC
[0308]
[0309] 38 UCUGUGAUGGC represented in the sequence listing as TCTGTGATGGC
[0310] Example 2 The local sequence context supports efficient recognition of the endogenous TIS
[0311]
[0169] We wondered to what extent the surrounding sequence is contributing to TIS recognition. To address this question, we adapted the RiboScan reporter (Figure 4A, B,) for lentiviral transduction, allowing precise measurements of leaky scanning for thousands of mRNA variants. The RiboScan reporter expresses two fluorescent proteins each representing the translation of one ORF. The mCherry fluorophore reports on start codon recognition of the main start codon. The GFP fluorophore reports on leaky scanning ribosomes, which failed to recognize the main start codon and its sequence is encoded in the +1 frame. The synthesis of GFP is initiated on an AUG start codon in strong sequence context (Kozak consensus sequence; GCCACCAUGGC-SEQ ID NO: 7) that is part of the reporter sequence. We precisely inserted the 5’UTR sequence of hundreds of human genes together with the first 18 nucleotides of the coding sequence of human transcripts directly downstream of the TSS of the CMV-promoter and before the RiboScan reporter via large scale library cloning (). Considering that the length of 5'UTRs affects start codon recognition efficiency we obtained 5’UTRs sequences of three different 5’UTR length ranges; between approximately 30 and 35, 70 and 75, and between 90 and 95 nucleotides. The reporters were stably integrated in the genome of HEK293T cells via lentiviral transduction. The MOI (<10% of cells infected) was kept low to ensure the integration of only one construct per cell, since multiple integrations prohibit precise coupling of the fluorescence signal to the integrated sequence element. After integration of the reporters in the cells and selection with puromycin, we generated FACS-seq libraries. To control for heterogeneity in expression, cells were sorted based on their GFP to mCherry ratio. Sequencing libraries were prepared and analysed. Overall, we observe good correlations of the obtained GFP levels between experimental repeats (). A set of control reporters was made allowing for the conversion of the GFP intensities to the absolute fraction of ribosomes that failed start codon recognition of the main start codon (). We obtained leaky scanning values of over 500 mRNA sequences obtained from human genes (). Surprisingly, although weak TISes (TIS score <65) generally tend to have more leaky scanning than strong TISes, the levels of leaky scanning poorly correlate with TIS strength (). Despite considerable variability in the efficiency of start codon recognition, start codons in TISes with a strength above 65 are generally efficiently recognized and the median percentage of leaky scanning amounted to 1.5%. This value is somewhat lower than we reported previously based onmeasurements obtained with translation imaging. However, the number of mRNAs on which alternative initiation was assessed with both methods was small. Additionally, as highlighted below the TIS and the flanking sequence of the gene are often co-adapted to each other. Potentially the higher levels of leaky scanning observed by translation imaging may result from an imperfect coupling between TIS and gene sequence in the assessed sequences. Approximately 20% (104 / 521 ) of the transcripts assessed here exhibited leaky scanning values above 5%. Transcripts with short 5’UTRs (~30 nucleotides) exhibit higher levels of leaky scanning than transcripts with longer 5’UTRs (~70 to 90 nucleotides), in line with translation initiation being less efficient on transcripts with short 5’UTRs ().
[0312]
[0170] In addition to the WT sequences, we generated three mutants per gene, in which the native TIS was replaced with a foreign TIS of equivalent strength. If the gene sequence does not interfere with the efficiency of start codon recognition, no change in start codon recognition between the native TIS and the foreign TIS is expected. Surprisingly, however, start codons were generally less well recognized when placed in a foreign TIS , irrespective of the transcript’s 5’UTR length and the TIS strength (Figure 5A). Note that a positive value in the heatmap corresponds to a reduction in start codon recognition and an increase in leaky scanning (more GFP expression). On average, the efficiency of start codon recognition was 2.4-fold lower in the foreign TISes than in the native TISes. Of note, the fold change in leaky scanning is relative to that of the native TIS. Transcripts with a weak native TIS, on which already a significant number of ribosomes undergo leaky scanning, will experience a bigger change in the absolute numbers of leaky scanning ribosomes than transcripts with a strong TIS on which leaky scanning is generally low. In conclusion, this finding provides the first indication that TIS and gene sequence are adapted to each other to enhance the efficiency of start codon recognition.
[0313]
[0171] Interestingly, for a small number of transcripts, start sites were more efficiently recognized upon TIS exchange, indicating that for these genes the native TIS was not well adapted to the flanking sequence. Notably, these transcripts more frequently contained a downstream in frame AUG (Figure 5B). Initiation on downstream in frame AUGs leads to the synthesis of N-terminally truncated proteins. Inefficient recognition of the native TIS sequence could therefore hint towards regulated leaky scanning in order to produce these N-terminal truncated protein isoforms. Analysis of ribosome profiling data confirmed a high degree of downstream AUG usage. The transcript encoding the transmembrane protein TMEM222, for example, contains a downstream in frame AUG. Translation initiation on this downstream start codon creates an N-terminally truncated isoform that lacks the transmembrane domain. Similarly, initiation on a downstream start codon of the transcript encoding the HACD1 protein creates a truncated protein isoform with a significantly shortened intrinsic disordered region.In summary, start codons that are inefficiently recognized by the ribosome in their native TIS often contain a downstream AUG codon, enabling the synthesis of different protein isoforms. The observation that in some genes the native start codon is not efficiently recognized by the ribosome is in line with a previous study, which reported that translation initiation on downstream start codons coevolved with the Kozak context of the protein-coding start. However, our results indicate that it is not simply the TIS and its strength that enable different protein isoform expression through leaky scanning. The TIS has to coevolve with the surrounding gene sequence to enable leaky scanning to occur.
[0314]
[0172] To further confirm that native TISes are generally optimally adapted to the flanking sequence, we examined single nucleotide substitutions in the TIS sequence. In line with the previous results, single nucleotide substitutions to the TIS predominantly enhanced leaky scanning. Single nucleotide substitutions that did not change the TIS strength typically reduced recognition of the main start codon. Surprisingly, even substitutions that strengthened the TIS according to the current model often led to a reduction in start codon recognition. Together, these observations suggest that the local sequence context functions alongside the endogenous TIS sequence to regulate start site recognition, usually to maximize the efficiency of start codon recognition.
[0315]
[0173] To study the coupling between TIS and the surrounding sequence of the gene more systematically, we cloned the 5’UTRs and the first 18 nucleotides of the CDS of 300 genes in the RiboScan reporter. Additionally, for each gene we generated 30 variants in which the native TIS was replaced with a foreign TIS. Importantly, the 30 foreign TISes were shared among all 300 genes to directly examine the impact of the local gene sequences on the recognition of the start codon in the foreign TISes. From this analysis two conclusions regarding start codon recognition can be drawn: 1. The strength of the TIS affects start site recognition. Start codon recognition in foreign TISes with weak TIS strengths (TIS strengths <86) occurs less efficiently than in foreign TISes with strong TIS strengths (TIS strengths >86). Of note, the reported TIS strength does not unceasingly correspond to the observed level of start site recognition. For some TISes, this is due to the introduction of a second downstream AUG (AAUUAUAl / GAU (SEQ ID NO: 22) and UACCUUAUGAU (SEQ ID NO: 23)) , while for others (UUGCUUAt / GGA (SEQ ID NO: 24), GGAAAAAt / GCG (SEQ ID NO: 25) the initial TIS strength may have been misannotated. Transcripts with the Kozak consensus sequence exhibit the lowest level of GFP expression, confirming the highly efficient recognition of the start codon in this sequence context. 2. There is significant variability in start site recognition among genes that share the same foreign TIS. Depending on the TIS sequence, differences in start codon recognition are observed up to 100-fold between genes. Even for relatively strong TISes a spread in start site recognition can be detected. For the strong TIS sequence, GUUGCAAl / GCU (SEQ ID NO:26), for example, a change of over 25-fold is detected between genes. To ensure that the difference in GFP levels between genes with the same TIS sequence is not caused by the introduction of sequence elements such as a downstream in-frame start or stop codon, variants in which these motifs occur were excluded from the analysis.
[0316]
[0174] Only 9.876 out of 65.536 possible TIS sequences are used in the human transcriptome for protein synthesis (Based on Ensembl Canonical Transcripts, Ensembl Release 110, July 2023). It could be that naturally occurring TISes have evolved to enhance start codon recognition and to limit leaky scanning. This, however, seems unlikely, given the large variability in start codon recognition of naturally occurring TISes .
[0317]
[0175] We propose, without being bound by any particular theory, two scenarios to explain the differences in start codon recognition between genes; 1. Interdependent Specificity -Specific interactions between the TIS sequence and the adjacent gene sequence regulate the efficiency of start codon recognition. A particular gene-TIS combination may be especially well fitted to enhance start codon recognition, while another TIS with the same flanking sequence impairs proper recognition of the start codon. Thus, effective start codon recognition relies on the compatibility between the TIS and its surrounding sequence. 2. Translation Initiation Sequence independency - The surrounding gene sequence determines the efficiency of start codon recognition irrespective of the TIS sequence. In this case, gene flanking sequences can be inherently classified as good or poor translation initiators.
[0318]
[0176] In reality, we observe a combination of both scenarios. Some combinations of TIS sequences and gene flanking sequences indeed enhance or reduce start codon recognition specifically. Surprisingly, we also identify both good and poor initiator sequences that function independently of the TIS sequence ). TISes can be classified in three groups; the first group contains typically weak TIS sequences, that irrespective of the surrounding sequence are inefficiently recognized. The second group contains TISes of moderate strength. The recognition efficiency of these TISes is dependent on the surrounding sequence of the gene. The gene sequence can either significantly enhance or impair start codon recognition. The third group contains TIS sequences that are generally efficiently recognized among the majority of genes, although still some effects of the gene sequence on start codon recognition can be observed (for example for the TIS GUUGCAAl / GCU (SEQ ID NO: Y)). To rule out the possibility that sequence features, previously found to reduce the efficiency of start codon recognition, are responsible for the gene-specific efficiency of start codon recognition, we compared the levels of start codon recognition between transcripts with or without nearcognate start codons. Additionally, we examined the effect of mRNA secondary structure on GFP expression levels for several TIS sequences studied. Our analysis showed no correlation between GFP levels and the presence of near-cognate start codons in the GFP frame, norbetween the minimal free energy (MFE) of the mRNA secondary structure and the GFP expression levels.
[0319]
[0177] Consistently, an mRNA encoding strong (S) distal nucleotides showed highly efficient start codon recognition even in the context of a weak (W) TIS. Notably, start codon recognition efficiency for this mRNA even exceeded that observed for an mRNA harboring a strong TIS and weak distal nucleotides (Figure. 5D). Together, these results identify key distal nucleotides that are important for start codon recognition and show that these distal nucleotides are at least as potent as TIS nucleotides in promoting start codon recognition. Since we find that nucleotides within the -40 to +39 region are potent modulators of start codon recognition, we refer to this region as the extended TIS (eTIS) and to the part of the eTIS that 261 flanks the classical -6 to +5 TIS, as the ‘distal eTIS'
[0320]
[0178] The effect of individual distal eTIS positions on start codon recognition was visualized using dot plots (Fig. 5-E-J). For each gene, we identified the two nucleotides exhibiting the largest difference in start codon recognition efficiency (the most optimal and least optimal) and calculated the log2(Fold change) in GFP expression between these nucleotides (Fig 5E-J). To improve visualization outliers were removed from the graphs (the 2% of genes showing the weakest and strongest changes in start codon recognition were excluded from the plots).
[0321]
[0179] Finally, we compared the obtained GFP values for the native TISes with those obtained for the foreign TISes. We find that also in this dataset native TISes are better recognized in their own context than foreign TISes of the same strength (Figure 5C. While the differences in start codons recognition between foreign and native TIS sequences are most pronounced for TISes with weak TIS strengths, the contrast between foreign and native TISes remains for strong TISes.
[0322]
[0180] We conclude that, contrary to common presumption, the TIS sequence does not solely determine the efficiency of start codon recognition. Instead, the local gene sequence surrounding the TIS also contributes to the efficiency of start codon recognition by the ribosomes. Moreover, the TIS and its surrounding gene sequence are mutually adapted to set the precise levels of start codon recognition. Consequently, start codon recognition on native TISes is generally more efficient than on foreign TIS variants with the same TIS strength. In the small number of instances where native TISes are not well compatible with the surrounding sequences, there might be underlying biological explanations, such as programmed leaky scanning to produce N-terminally truncated protein isoforms.
[0323] Example 3 Distal sequences influence start site recognition
[0324]
[0181] To map the precise regions of the 5’UTR and the coding sequence that can modulate start codon recognition, we applied a large-scale mutagenesis approach. We created a newlibrary that contained thousands of mutant sequences . The mutations were tiled over the entire length of the 5’UTRs and the included fraction of the coding sequence for each gene. Per tiling window five consecutive nucleotides were mutated and the tiling windows were not overlapping. Translation initiation is heavily dependent on the sequence of the TIS . Since two of the tiles (-10 to -6 and +4 to +8) contain bases of the TIS sequence, which spans the region in the mRNA from the -6 to the +5 nucleotide relative to the A of the AUG, we created two additional mutation tiles; one spanning nucleotides -10 to -7 upstream of the AUG and one containing nucleotides +6 to +8 downstream of the AUG. To maintain a similar GC-content, which affects several parameters of mRNA homeostasis including mRNA stability and mRNA export , adenosine was mutated to thymidine and cytosine was mutated to guanine. The opposite mutations, G to C and T to A were introduced simultaneously. For several transcripts, each nucleotide was mutated individually, instead of in clusters of five nucleotides.
[0325]
[0182] The calculated GFP expression levels obtained after FACS-seq (See Methods) matched the expression levels of single library elements as determined directly by FACS and the obtained GFP levels after FACS-seq correlated well for the two technical repeats . For each mutation, the Iog2 fold change in GFP intensities between the mutant and the wild type sequences was determined and the Iog2 fold changes were plotted over the length of each transcript (data not shown). Mutating the TIS bases in the two mutation tiles directly upstream and the one tile downstream of the AUG start codon resulted in large changes in start codon recognition. The Kozak consensus sequence is the result of a selection pressure to optimize start codon recognition. Changing the Kozak bases therefore most often led to an increase in GFP levels, indicative of reduced start codon recognition. Single nucleotide substitutions confirmed the importance of the essential Kozak base at position -3 and changing the -3 nucleotide almost exclusively resulted in a significant reduction in start codon recognition. Interestingly, also mutations outside of the TIS region contributed to changes in start codon recognition. Since the introduced mutations are dependent on the wild type sequence, it could be that by chance alternative start codons or stop codons are lost or introduced which would deregulate the translation initiation processes. Especially the introduction of an upstream start codon in the +1 frame, in frame with the GFP, resulted in elevated GFP expression levels. Moreover, the introduction of downstream stop codons in frame with the main start codon also increased the levels of GFP expression, most likely due to reinitiation of the ribosome on one of the three downstream AUGs in the RiboScan reporter, which drive the expression of GFP. Although these mutations and the mutations around the TIS indicate that our reporter is functioning correctly, their presence or absence is directly responsible for the changes in GFP expression rather than influencing the recognition of the main start codon and they were therefore excluded from further analysis.
[0183] To obtain the mutations that cause a significant change (> 1.25-fold) in the GFP intensity values, we performed differential expression analysis (See Methods). Many genes (about 200 out of 500, 40%) had at least one mutation outside of the TIS that caused a significant change in start codon recognition. For several genes mutations of multiple consecutive tiles caused a significant change in start site recognition. This could hint towards a local mRNA secondary structure that is disrupted by each of the introduced mutations. Even mutations introduced far upstream, in proximity to the 5’ end of the mRNA, could alter the levels of start site recognition (MYL9). 5’RACE was performed to validate that these mutations did not cause a change in transcription start site usage . In many cases, single nucleotide substitutions had a similar effect on start site recognition as the mutation tiles of five nucleotides. The significant changes do not exhibit a directional bias towards changes that impede start site recognition. Such a directional bias is expected if mRNA sequences would be optimized to maximize start codon recognition. Motif enrichment analysis (See Methods), however, revealed several mutations that are locally enriched and directionally biased towards a certain change in start site recognition. For example, the introduction of the sequence motif GCGG in the tiling window just upstream of the TIS (-10:-7) causes an increase in leaky scanning, while the introduction of the sequence motif WWAA generally enhances start codon recognition when positioned at -16 to -13. Even motifs downstream of the start codon influence the efficiency of start codon recognition such as the motif AGANT, most often present at position +9 to +14.
[0326]
[0184] If the mRNA sequence around the TIS contributes to the efficiency of start codon recognition by the ribosome, we expect the mutations around the TIS, most likely within the ribosomal footprint (-15 to +15), to affect the efficiency of start site recognition most strongly. To validate this hypothesis, we quantified the percentage of mutations that cause a significant change in start codon recognition per mutation tile. If start codon recognition is affected most by the mutations around the AUG, we expect this percentage to peak in the mutation tiles around the AUG.
[0327]
[0185] Indeed, the closer a mutation is introduced to the AUG, the more important it is for start codon recognition (Figure 6A). Similar observations are made for all tested UTR lengths as well as for the dataset including the single nucleotide substitutions (Figure 6B). For the transcripts with a UTR length of 70 and 90 nucleotides, the most upstream mutation tiles do not significantly change start codon recognition. Potentially, these mutations are positioned too distal from the AUG to have any influence on AUG recognition by the PIC or to undergo any interactions with the proteins that are associated with the PIC and extend beyond the ribosomal footprint. The number of affected genes, thereafter, steadily increases. Fortranscripts with a UTR length around 30 nucleotides, even exchanging the most 5’ bases cause a change in start site recognition.
[0328]
[0186] Mutations introduced in the window directly downstream of the TIS (+6 to +8) most often contributed to a change in start site recognition, followed by the subsequent window (+9 to +14) and the first window upstream of the TIS (-10 to -7). To further map the regions downstream of the main start codon that are important for start codon recognition, we created a different library in which we introduced the 5’UTR (between 30 and 35 nucleotides) and the first 93 nucleotides of the coding sequence. Genes were selected to have no downstream AUG in any of the three reading frames to prevent interference with reporter readout. Of note, changing the coding sequence immediately downstream of the AUG in the RiboScan reporter will not generally affect GFP expression, since the fluorescent GFP signal stems from initiation events in a different reading frame downstream of the introduced sequence. Surprisingly, the seemingly linear relationship between the relative position of the mutations to the AUG start codon and the number of affected genes is also observed downstream of the AUG (Figure 6C). The coding sequence, in addition to providing the amino acid sequence of the protein, can thus also influence the efficiency of protein production.
[0329]
[0187] To examine the contribution of alternative initiation in the +1 frame, which would contribute to the GFP signal obtained with the RiboScan reporter, a stop codon was introduced upstream of the GFP start codons. Stop codon introduction should terminate all +1 translation stemming from alternative initiation events upstream of the GFP in the gene sequence (5’UTR + CDS). Comparing the levels of start site recognition in libraries with and without a stop codon revealed that variants with an AUG in the +1 frame are significantly affected by the introduction of the stop codon, as indicated by a reduction in GFP expression and a shift from the diagonal . Other sequences remained located near the diagonal and thus are not affected by the introduction of the stop codon. The changes in start codon recognition upon the introduction of the distal sequences are therefore likely not a result of alternative initiation in the +1 frame on near cognate start codons but stem from leaky scanning of the main start codon.
[0330]
[0188] In conclusion, mRNA sequences on both sides of the start codon can affect start codon recognition over a considerable distance but are more likely to influence start codon recognition in proximity to the start codon.
[0331] Example 4 Distal sequences function in start codon recognition independently of the TIS
[0332]
[0189] Earlier experiments showed that distal sequences may influence start codon recognition. Next we set out to test if this happens through direct interactions with the TIS. For each transcript with a distal mutation that significantly altered start codon recognition, wetherefore generated several sequence variants. Specifically, the native TIS in each transcript was mutated into three different foreign TIS sequences, each with strengths comparable to the native TIS sequence. Additionally, for each TIS mutant, a second variant was created incorporating the distal mutation that significantly altered start codon recognition of the native TIS. Mutating the native TIS resulted in significant changes in start codon recognition, even though a similar TIS strength was used. As highlighted before, this is most likely due to coupling between the TIS and the gene sequence. We compared the changes in start codon recognition between the foreign TIS sequences with and without the distal mutation. If the distal sequences regulate the recognition of the native TISes, the efficiency of start codon recognition of the foreign TISes should not be affected by the introduction of the distal mutations. Surprisingly, we find that the changes in start codon recognition upon the introduction of the distal mutations remain consistent across all TISes, native or foreign, for nearly all distal mutations (Figure 7A ). The direction and the magnitude of the changes in start codon recognition caused by the mutations are largely unaffected by the identity of the TIS. Additionally, neither the length of the 5’UTR nor the positions of the distal mutations in the mRNA influences the change in start codon recognition upon the introduction of the foreign TIS sequences (Figure 7B,). This suggests that the impact of the distal sequences on start site recognition is largely independent of the TIS sequence (Sequence independency). We conclude that distal sequences influence start codon recognition independently from the TIS sequence. This observation is at odds with a model that describes compatibility between the native TIS and the gene sequence, since according to this model no sequence alteration outside the TIS region should enhance the efficiency of start codon recognition.
[0333]
[0190] We wondered whether the nucleotide identity of the distal sequences influences start codon recognition. Therefore, we created a set of alternative mutations at the same distal positions. Studying the effects of different mutations may help to understand whether the initial mutation (hereafter defined as original mutation) disrupted a regulatory element or introduced one. If the alternative mutations affect start codon recognition similarly to the original mutations, it suggests that the original mutation disrupted a regulatory element in the wild-type sequence. Conversely, if the alternative mutations do not change start codon recognition, the original mutation might have functioned as a regulatory element on its own.
[0334]
[0191] For each five nucleotide long mutated tile that significantly changed start codon recognition, we created two alternative mutant sequences. The WT sequences at these positions were modified by either substituting A with C and T with G, or by changing A to G and T to C, along with their corresponding inverse mutations. The original mutations can be classified into two groups: those that improve the efficiency of start codon recognition and those that diminish it. We find that, if the original mutation reduced start codon recognition ofthe main AUG, the two alternative mutations on average did not (Figure 7C). This suggests that the new sequence introduced with the original mutation likely functions as a repressor of start codon recognition of the main AUG. The decrease in start codon recognition upon the introduction of the original mutation correlates with an increase in mRNA secondary structure. In contrast, the mRNAs with the two alternative mutations are generally less structured. Potentially, the change in start codon recognition could thus be a result of a change in mRNA secondary structure specific to the original mutations. Only in a small subset of transcripts, all three mutant variants cause a reduction in start codon recognition. In these transcripts, the WT sequence likely contains a sequence motif that enhances start codon recognition and disruption of the motif upon the introduction of any of the three sequence mutants presumably reduced start codon recognition and stimulated leaky scanning. If the original mutation caused an increase in start codon recognition, the two alternative mutations, on average, also caused an increase in start codon recognition (Figure 7C). This observation is surprising, as it suggests that the default state of the WT mRNA sequence is to allow a certain number of ribosomes to scan over the main AUG. The increase in start codon recognition is associated with a reduction in the secondary structure of the mRNA transcripts. In summary, it appears that distal sequences influence the efficiency of start codon recognition by modulating mRNA secondary structure. Distal sequences that enhance the secondary structure of the mRNA sequence reduce the efficiency of start codon recognition by the ribosome.
[0335] Example 5 The +6 nucleotide identity influences start codon recognition efficiency
[0192] The mutation tiles directly adjacent to the main AUG (those containing nucleotides -10 to -7 and +6 to +8) exhibit the highest number of transcripts with significant changes in start site recognition. This led us to investigate whether nucleotides within these mutation tiles might act as extensions of the TIS to regulate start codon recognition. In the mutation tile directly downstream of the TIS (nucleotides +6 to +8), a clear pattern emerged when the genes were grouped according to the identity of the +6 nucleotide. Substitutions from +6G to +6C or from +6U to +6A generally reduced translation initiation from the main start codon. Conversely, substitutions from A to U or C to G at the +6 position generally increased start codon recognition. The substitutions of the +7 and +8 nucleotides, that were introduced simultaneously with the +6 substitutions, did not clearly affect start codon recognition. Single nucleotide substitutions at the +6 position confirmed the same correlations, with the additions that +6A to +6G and +6C to +6U substitutions also led to an increase in start codon recognition. Mutating the +7 and +8 nucleotides to other nucleotides did not cause a consistent change in start codon recognition , suggesting that the ability to affect start codon recognition is limitedto the +6 nucleotide. In conclusion, our mutagenesis screen identified the +6 nucleotide as a novel determinant of translation initiation.
[0336]
[0193] We established that the endogenous TIS and the transcript-specific sequence surrounding it are mutually adapted to precisely control the efficiency of start codon recognition. Introducing foreign TISes in transcripts, thereby breaking the coupling between the native TIS and the surrounding sequence, resulted in substantial worse start codon recognition among most genes. Considering the correlation between the identity of the +6 nucleotide and start codon recognition, we questioned whether poor coupling between foreign TISes and gene sequences could partly be attributed to the identity of the +6 nucleotide in the transcripts. A comparative analysis of genes with identical TISes, revealed a clear connection between the identity of the +6 nucleotide and the efficiency of start codon recognition. Genes with a +6A or a +6C generally exhibited higher GFP levels, indicative of reduced start codon recognition, compared to genes with a +6G or a +6U (Figure 8A). Overall, the median GFP values of genes with a +6A or a +6C are 1.73 and 1.53 fold higher than those with a +6G, respectively. Additionally, genes with a +6U showed about 1.12 times higher GFP levels than genes with a +6G . The effect that the +6 nucleotide exerts on start site recognition is largely maintained with TIS strength. Some TIS sequences, however, seem not to be affected by the identity of the +6 nucleotide, for example the canonical Kozak sequence, GCCACCAUGGC, while others specifically benefitted more from a +6G over a +6A (for example: GGAGGCUAUGGG) or over a +6C (for example: UUGCUUAUGGA). The nucleotide identify at the +7 and +8 positions did not alter the efficiency of start site recognition . It is important to note that the sequence similarity among the genes in the dataset is small. Nucleotides at all positions in the transcripts could theoretically have contributed to the large variance in start codon recognition between the genes. The observed correlation between the identity of the +6 nucleotide and the efficiency of start codon recognition, despite the significant sequence variation among the genes, therefore highlights the crucial role of the +6 nucleotide in start codon recognition. The +6 nucleotide, however, is not solely responsible for the existence of good and poor initiator sequences. Grouping the transcripts by the identity of the +6 nucleotide reveals that for every +6 nucleotide, both good and poor initiator sequences exist.
[0337]
[0194] In conclusion, through large-scale mutagenesis we have identified the +6 nucleotide as a novel factor involved in the process of start codon recognition. The effect of the +6 nucleotide on translation initiation can be observed across a large set of transcripts, and partly explain the large variation in start codon recognition between genes. Start codon recognition benefits most from a guanine or a uracil at the +6 position. An adenine or a cytosine at the +6 position weakens start codon recognition by the ribosome. The effect that the +6 nucleotide exerts on start site recognition seems independent of the TIS sequence and strength.Example 6 A GG motif directly upstream of the Kozak sequence reduces start codon recognition
[0338]
[0195] Analysis of sequences upstream of the TIS (nucleotides -10 to -7), did not reveal strong correlations between the exchange of a single nucleotide within the tile and changes in start codon recognition, such as those observed for the +6. Motif enrichment analysis, however, revealed the presence of a strong motif (GCGG) in this region which often reduced start codon recognition once introduced. Upon further investigation of this motif, we identified that C to G mutations at positions -8 and -7 enhance GFP expression and thus reduce the efficiency of start codon recognition. Similar changes in the efficiency of start codon recognition were observed when analyzing the effects of single nucleotide substitutions at these positions. Correlations between the exchange of dinucleotide motifs at positions -9 and -8 or -10 and -9 and start codon recognition were less evident. The dinucleotide motifs AG and UG at position -9 and -8 in the majority of cases reduce start codon recognition. At positions -10 and -9 the motifs UA and UU diminish start codon recognition.
[0339]
[0196] The finding that the motif CGG at positions -9 to -7 reduces start codon recognition aligns with a previous report in which the motif GCC was shown to enhance start codon recognition for one model mRNA sequence. Surprisingly, in our experiments changing the nucleotides at positions -8 and -7 to CC did not generally improve start codon recognition. It has been suggested that -8C and -7C enhance start codon recognition only when accompanied by a -9G. However, NCGG to NGCC mutations did not specifically enhance start codon recognition. Given these observations, we propose an alternative hypothesis in which we envision a disruptive role in start codon recognition for -8G and -7G. Although the GCC motif may enhance start codon recognition in specific sequence contexts, especially when followed by a second GCC repeat at positions -6 to -4, based on our current data, it does not appear to be a general enhancer of start codon recognition.
[0340]
[0197] In conclusion, in addition to the +6G nucleotide, we have identified several novel dinucleotide sequence motifs upstream of the Kozak sequence that influence start codon recognition. Particularly, guanine nucleotides at positions -8 and -7 appear to have a significant impact, notably reducing the efficiency of start codon recognition.
[0341] Example 7 +6G is specifically enriched in transcripts with short 5’UTRs
[0342]
[0198] Previous studies with reporter mRNAs have demonstrated that start codons positioned near the mRNA cap are inefficiently recognized by the PIC and likely subjected to leaky scanning. This prompted us to investigate whether TISes within transcripts with short 5’UTRs might have evolved to improve TIS recognition and impede leaky scanning, such as bystrengthening the local sequence context of the AUG. Transcriptome-wide analysis reveals that the average TIS strength increases once the 5’UTR decreases below 50 nucleotides. Closer inspection of the TISes in short 5’UTRs revealed that the increase in TIS strength is due to an increase in +4G and +5C use. Removing all transcripts with a +4G and a +5C eliminated the length dependent decrease in TIS strength. The enhanced TIS strength by the incorporation of +4G and +5C may counteract the suboptimal recognition of TISes in transcripts with short 5’UTRs.
[0343]
[0199] Having established a role for the +6 nucleotide in translation initiation, we next wondered whether the frequencies of +6 nucleotides that enhance translation initiation are particularly increased in transcripts with short 5’UTRs. Given the relationship between +4G and +5C use and UTR length, we started out by investigating the +6 nucleotide frequency of alanine codons, encoded by GCN. Alanine is the most frequent second amino acid in vertebrate proteins, and is particularly often encoded by the rare GCG codon. Surprisingly, the frequency of GCG codon usage is 5’UTR length dependent. For short 5’UTRs GCG is indeed the most frequently used codon; it is used in nearly 40% of the transcripts with an alanine codon as the first coding codon (. However, with increasing UTR length, the GCG codon frequency decreases, until it plateaus at approximately 7.5% when the 5’UTR length exceeds 75 nucleotides.
[0344]
[0200] Having established a link between 5’UTR length and the +6G nucleotide frequency in alanine codons, we wondered how the nucleotide frequency of the +6 nucleotide changes with 5’UTR length transcriptome-wide. We find that the +6G nucleotide frequency decreases from approximately 65% to 40% as the 5’UTR length extends beyond ~75 bps . +6G use is particularly present in transcripts with a length between 11 and 25 nucleotides. Given the specific enrichment of GCG codons as the first coding codon in transcripts with a short 5’UTR, we wondered whether the +6G enrichment in transcripts with short 5’UTRs could be a direct result of the occurrence of the GCG codon. However, even after the removal of all alanine codons a bias for +6G remains for transcripts with short 5’UTRs. The increase in +6G usage for transcripts with short 5’UTRs is thus not solely GCG codon dependent. Additionally, the reduction of +6G with increasing 5’UTR length is not likely a result of changes in the frequencies of other amino acids encoded by the first coding codon, since alanine is the only amino acid for which the amino acid frequencies clearly correlate with 5’UTR length. The enhanced use of guanine at the +6 position for transcripts with short 5’UTRs therefore is a result of the specific usage of codons with a G at the third base.
[0345]
[0201] The increase in the +6G frequency in transcripts with short 5’UTRs could be the result of other sequence features, such as a difference in the nucleotide frequency due to the G-bias around the TIS and the genomic distance between the TSS and the start codon. To this end,we computed the nucleotide frequency at the +6 position and the +9 and +12 position over a range of different 5’UTR lengths. Clearly, +6G usage is more abundant for short 5’UTRs compared to guanine usage at the +9 and +12 position in transcripts with a similar 5’UTR length. The +6G enrichment for short UTRs is thus not a result of the general enrichment in G content. Even if alanine codons are excluded from the analysis, guanine is more frequently used at the +6 position than at the +9 or the +12 position. The genomic distance between the TSS and the start codon can affect nucleotide selection at the +6 position. However the genomic distance between TSS and start codon does not significantly influence the nucleotide choice at the +6 position for short 5’UTRs since over 88% of transcripts with 5’UTRs shorter than 75 nucleotides do not contain an intron between the TSS and the start codon.
[0346]
[0202] In conclusion, mRNA transcripts with short 5' UTRs may have evolved specific sequence features to improve start codon recognition, which is typically considered inefficient on these transcripts. These transcripts often feature an increased usage of guanine and cytosine at the +4 and +5 positions, thereby strengthening the sequence context of the start codon. Generally, transcripts with short 5' UTRs tend to use guanine more frequently at the +6 position compared to those with moderate or long 5' UTRs. The enrichment in guanine usage seems to be restricted to the +6 position. Since guanine at the +6 position enhances start codon recognition, its presence likely contributes to more efficient start codon recognition in these transcripts.
[0347] Example 8 +6G frequency is enhanced on transcripts with a start codon in a poor sequence context
[0348]
[0203] The +6G or +6U nucleotides can enhance start site recognition either dependently or independently of the TIS sequence. Especially weak TISes might benefit from favorable +6 nucleotides, as start codon recognition on weak TISes is generally inefficient and causes leaky scanning of the AUG codon. +6 nucleotides that promote translation initiation could compensate for the poor sequence context of the AUG codon and strengthen the TISes. Consequently, +6G and +6U are expected to be more prevalent downstream of weak TISes. Alternatively, the +6 nucleotide might function independently from the TIS, aiming to maximize start codon recognition across all TISes. A +6 nucleotide that operates autonomously from the TIS would enable cells to enhance protein production while retaining a flexibility in the selection of the second amino acid, which is determined by the +4 and +5 nucleotide.
[0349]
[0204] To distinguish between these possibilities, we compared the +6 nucleotide frequency to the TIS strength. Given the enrichment of +6G on short 5’UTRs, only transcripts with a UTR length >100 were included in the analysis. To avoid potential bias from amino acid preference, particularly for amino acids that can only be encoded by codons with two out of four nucleotidesat the third base, we only considered codons that share the first two bases and encode for the same amino acid, irrespective of the identity of the third base of the codon. The data indicated that with increasing TIS strength, the abundance of +6G decreases. The use of +6A remains relatively constant across TIS strengths, while +6C and +6U frequencies increase with increasing strength. This observation thus supports the hypothesis that +6G is enhanced on TISes in a weak sequence context, potentially to enhance the translation from these initiation sites. When including all mRNAs, the graph remains similar, up to a TIS strength of about 112. Above this strength, the frequency of +6G increases again. As mentioned, TIS strength increases specifically for transcripts with short 5’UTRs due to an increase in the use of GC at position +4 and +5 and a rise in the use of the GCG codon as first coding codon, in particular. Therefore, the increase in the +6G frequency for strong TISes can be attributed to an increase in the use of the GCG codon in transcripts with short 5’UTRs.
[0350]
[0205] Given the observation that +6G frequency inversely correlates with TIS strength, we wondered whether the +6G frequency is also elevated near weak start codons of validated translated uORFs. Similar to protein-coding start codons in poor sequence contexts, start codons of uORFs that are in a weak sequence context show elevated use of +6G. The +6G enrichment thus appears to be a general feature of translated ORFs. As a control we investigated the +6 nucleotide frequency downstream of AUG start codons of uORFs and overlapping ORFs (oORFS) that are not reported to be translated. For these start codons no correlation between TIS strength and +6G frequency was observed, suggesting that the use of +6G could be a feature of translated ORFs, particularly those with start codons in a suboptimal sequence context.
[0351] Example 9 Cytosine nucleotides are enriched in transcripts with short 5’UTRs at positions -7 and -8
[0352]
[0206] Given the conservation of the +6G nucleotide in the transcripts and its enrichment in transcripts with short 5’UTRs and transcripts with start codons in weak sequence contexts in particular, we investigated whether similar patterns could be observed for the sequence motifs upstream of the Kozak sequence. We began by analysing the frequencies of single nucleotides upstream of the Kozak sequence. Apart from an enrichment of G at position -9 and a corresponding reduction in -9C, no other significant nucleotide enrichments were detected. The functional importance of the -9G nucleotide remains unclear, although current data suggests it may enhance start codon recognition.
[0353]
[0207] Subsequently, we investigated the enrichment of dinucleotides at position -8 and -7. Based on large-scale mutagenesis we anticipate the dinucleotide GG to be depleted from the transcriptome, since substituting CC with GG at these positions induces leaky scanning andimpairs start codon recognition. Indeed, the GG sequence is the most depleted dinucleotide at positions -8 and -7 (. Moreover, we find the dinucleotides CC and GC to be enriched at positions -8 and -7.
[0354]
[0208] The frequency of +6G is specifically enriched in transcripts with short 5’UTRs, that often do not contain an intron between the TSS and the start codon. Similarly, intronless transcripts with short 5’UTRs may have specifically depleted GG and enriched GC and CC at position -8,-7 to enhance start codon recognition. When separating transcripts by the presence or the absence of an intron between the TSS and the start codon, we find that both the reduction in GG frequency and the enrichment in CC frequency at positions -8 and -7 are diminished in transcripts with an intron . Additionally, in these transcripts GC is not enriched. The use of CC and GC dinucleotides thus appears restricted to intronless transcripts, in which the genomic distance between the TSS and the start codon is short. Interestingly, in transcripts without an intron in the 5’UTR the dinucleotide frequency of CC already exhibits an increase before the -8 and -7 nucleotides. Analysis of the cytosine content confirmed that for transcripts with a short genomic distance between the TSS and the start codon, the average cytosine levels rise towards the start codon, except at position -9 . In contrast, for transcripts with a large genomic distance between the TSS and the start codon, the cytosine frequencies slightly reduce towards the start codon. The functional relevance for the increase in cytosine levels towards the start codon in transcripts without an intron in the 5’UTR currently remains unknown. In summary, the dinucleotide GG is depleted in the transcriptome at positions -8 and -7 for transcripts without an intron in the 5’UTR. A reduction in GG frequency at positions -8 and -7 is expected based on our experimental data that shows that substituting CC with GG at positions -8 and -7 reduces the efficiency of start codon recognition by the ribosome. In addition, CC and CG are enriched at nucleotide positions -8 and -7 in the same group of transcripts. However, experimentally we cannot directly link these motifs to an enhanced efficiency of start codon recognition by the ribosome.
[0355]
[0209] Given the enrichment of -9G and the enrichment of CC and GC at positions -8 and -7, we investigated whether these motifs occurred together. Analysis of the trinucleotide frequencies revealed an enrichment of the triplets GCC and GGC at positions -9 to -7 . As expected, this enrichment was observed only for transcripts without an intron in the 5’UTR and was found not to extend further to the trinucleotide directly upstream. Moreover, the trinucleotides of the form NGG are generally depleted, in particular CGG. Unlike +6G, which is enriched in transcripts with short 5’UTRs, neither GCC nor GGC is enriched on transcripts with short 5’UTRs. The GCC frequency, in fact, increases with increasing 5’UTR length, peaking at a 5’UTR length of about 100 nucleotides for transcripts without an intron. Inconclusion, upstream of the TIS the triplets GCC and GGC are enriched in transcripts without an intron in the 5’UTR at nucleotide positions -9 to -7.
[0356] Example 10 Frequently occurring nucleotide sequences at nucleotide positions -9 to -7 are associated with weaker TISes
[0357]
[0210] Next, we investigated the correlation between the nucleotide frequencies of upstream bases at positions -9 to -7 and the strength of the TIS. Since the frequency of +6G anticorrelates with the strength of the TIS sequence (Figure 8B), potentially to enhance start codon recognition of weak TISes, we wondered whether a similar anticorrelation could be observed for upstream nucleotides. At positions, -8 and -7, the cytosine frequency is enriched for weak TISes, suggesting that -8 and -7C might function similarly to +6G in enhancing start codon recognition. Analysis of dinucleotide frequencies at positions -7 and -8, however, did not reveal any motif that correlated with TIS strength (data not shown). At the -9 position, guanine is not enriched near weak TISes; instead, it appears to be enriched for stronger TIS sequences. Surprisingly, despite cytosine being depleted at the -9 position, the cytosine frequency correlates negatively with TIS strength. Also at position -9 cytosine may therefore enhance start codon recognition. GCC and CCC are the only trinucleotides which frequencies negatively correlate with TIS strength.
[0358]
[0211] In conclusion, specific nucleotide motifs directly upstream of the TIS, such as -7C and the trinucleotide motif GCC, are enriched in the transcriptome, and are associated with weak TISes. Possibly, these motifs enhance the efficiency of start codon recognition by the ribosome, similar to +6G downstream of the start codon. The nucleotide enrichment appears to be specific for transcripts without an intron in the 5’UTR.
[0359] Example 11 Optimization of mRN A sequences for protein expression
[0360]
[0212] The identified motifs, whether it is the +6 nucleotide, the -8 and -7 nucleotides or sequence motifs positioned at a greater distance from the TIS could be applied for the optimization of protein expression. Importantly, most of the motifs, except for the longer sequence motifs introduced downstream of the start codon, will not alter the amino acid sequence of the encoded protein. This contrasts with enhancing protein expression by TIS optimization, which often requires mutating nucleotides at position +4 and +5 and thus likely affecting the identity of the amino acid encoded by the first coding codon. As a proof of principle, we here optimized the mRNA sequence of the NINJ1 transcripts (ENST00000375446.5) to enhance its protein expression. The TIS of NINJ1 mRNA has a moderate strength of 73 with critical Kozak bases, an adenine at the -3 position and a guanine at the +4 position. The efficiency of start codon recognition in the NINJ1 transcripts can thusnot be further enhanced by changing the nucleotides at critical Kozak positions. The NINJ1 is a suitable starting point for sequence optimization since a substantial amount of ribosomes leaky scan the main start codon on this transcript (-10-15%). To investigate the contributions of the identified motifs to start codon recognition we introduced each sequence element separately or combined several sequence elements together. The majority of the sequence elements individually led to a significant increase in start codon recognition, with the WWAA motif being the only exception. The most significant change in start codon recognition following the introduction of a single motif occurred when the +6C was replaced by +6G, resulting in a 4.66-fold increase in recognition. Although the introduction of cytosine nucleotides at positions -8 and -7 did not cause a major shift in start codon recognition, adding these mutations to the +6G mutation further increased start codon recognition with about 2-fold to 6.4 fold. Interestingly, the combined introduction of all sequence motifs enhanced start codon recognition by approximately 16-fold. This significant increase in the efficiency of start codon recognition indicates that the collective impact of all sequence motifs is greater than the sum of their individual contributions. Introducing all sequence motifs reduced the percentage of leaky scanning ribosomes to below -1% of total ribosomes that scan the NINJ1 mRNA transcript. It is important to note that the TIS sequence remains consistent across all variants. The substantial shift in the efficiency of start codon recognition observed upon optimizing the NINJ1 transcript thus emphasizes the crucial role of the surrounding sequence in TIS recognition.
[0361] Example 12 eTIS optimization for mRNA therapeutics
[0362]
[0213] We next aimed to leverage the discovery of the eTIS to optimize gene expression of a transgene. Findings outlining these optimizations are described in Figure 1A-1K wherein a wild-type (WT) eTIS is compared to an optimized (Opt.) eTIS. Most engineered transgenes, including those used in biomedical research and in clinical applications, are optimized for efficient start codon recognition using the Kozak sequence to increase expression levels and reduce 'off-target' protein production caused by downstream initiation. We reasoned that eTIS optimization could further improve transgene expression. To this end, we selected the nucleotide at each position that most strongly enhanced start codon recognition efficiency. Introduction of an optimized eTIS resulted in an almost complete elimination of GFP expression in almost all endogenous mRNAs tested (Fig. 1A, 1C and 1D), demonstrating that eTIS optimization results in highly efficient start codon recognition. eTIS optimization even allowed highly efficient translation initiation on CUG or GUG start codons, an effect that was not observed with TIS optimization alone (Fig. 1 B, highlighting the potency of eTIS optimization in enhancing start codon recognition. Even for vaccine (therapeutic) mRNAs which have alreadybeen extensively optimized, eTIS optimization substantially improved start codon recognition (Fig. 1E-G). Together, these results show that eTIS optimization results in near-perfect start codon recognition, eliminating off- target protein production caused by leaky scanning. To determine whether improved start codon recognition upon eTIS optimization also resulted in increased expression of the main frame protein product, we engineered a reporter mRNA in which GFP was encoded in the main frame (frame 0). Expression of mCherry was driven by an IRES from the same mRNA for mRNA expression normalization (. We first compared GFP expression levels in this main frame GFP reporter to GFP expression from the RiboScan reporter for the same set of sequences, which revealed a strong inverse correlation between both values, indicating that efficient start codon recognition enhances main frame protein production, as expected. Consistent with this, eTIS optimization of vaccine mRNAs resulted in a significant increase in GFP expression in most cases (Fig. 1H). eTIS optimization also enhanced start codon recognition in Cos7 and CHO-KI cells (Fig. 11, J), cell types frequently used for recombinant protein production, extending the potential applications of this approach in other species such as yeasts. Circular RNAs (circRNAs) are increasingly used in RNA-based therapeutics owing to their resistance to exonuclease-mediated degradation. Translation of circRNAs typically relies on IRESs to recruit ribosomes to the RNA. To determine whether eTIS optimization also improves start codon recognition during IRES-driven circRNA translation, we measured protein output from mRNAs encoding type I IRESs — which are often used for therapeutic protein expression — with either a strong or weak distal eTIS. Strong distal e TIS sequences consistently increased total protein expression (Fig. 1 K), indicating that distal eTIS residues promote start codon recognition in IRES-driven translation as well. Taken together, these findings demonstrate that eTIS optimization improves translational precision and enhances transgene expression for therapeutic applications.
[0363] Example 13 Adenosine and cytosine at -1 and -2 positions are strong enhancers of start codon recognition
[0364]
[0214] We re-examined nucleotide enrichment within the classical TIS to ask if the Kozak sequence, which is highly GC-rich is also affected by the promoter GO spike. When we examined nucleotide frequencies in the TIS for genes without an intron in the 5'UTR, the TIS consensus sequence was highly GC-rich and closely resembled the Kozak consensus sequence. In contrast, genes with an intron in the 5'UTR showed a TIS consensus that was more AU-rich. Interestingly, when comparing the two TIS consensus sequences with our TIS mutagenesis data, we found that the AU-rich consensus sequence of 5'UTR intron-containing genes matched the optimal sequence for start codon recognition more closely (R2=0.71 vs R2=0.46). Specifically, a uridine at -5 and adenosines at -3, -2 and -1 were more stronglyenriched in the intron-containing consensus sequences compared to intronless sequences, and these nucleotides performed very well in promoting start codon recognition in functional data. Surprisingly, while both adenosine and cytosine at -1 and -2 positions are strong enhancers of start codon recognition, the optimal nucleotide at -1 depends on the nucleotide at the -2 position, and vice versa; with adenosine being optimal when the other position contains a purine (e.g. another adenosine), while a cytidine outperforming adenosine if the other position contained a pyrimidine (e.g. another cytidine) (Fig. 9A, B). Such context-dependent strengths were only observed for the -1 and -2 positions within the TIS. Taken together, these findings strongly suggest that the Kozak sequence was 'polluted' by the promoter GC spike, and does not represent the optimal TIS for start codon recognition. Rather, the optimal TIS is represented by the sequence re-defining one of the most iconic and widely-used sequences in molecular biology and medicine.
[0365] CLAUSES
[0366] For reasons of completeness, various aspects of the invention are set out in the following numbered clauses:
[0367] 1 . A nucleic acid molecule encoding a protein, wherein the nucleic acid molecule (further) comprises:
[0368] (a) a start codon;
[0369] (b) a region, designated herein as an extended translation initiation site (eTIS), from position -40 to + 40 relative to the first nucleotide of the start codon (designated as +1), and wherein the region comprises at least one nucleotide modification compared to the corresponding region of a naturally occurring nucleotide sequence encoding the protein, preferably such that the amino acid sequence of the encoded protein is identical to that of the naturally occurring protein.
[0370] 2. The nucleic acid molecule according to clause 1 wherein:
[0371] (a) the nucleotide at position +6 is modified compared to the corresponding position in the natural sequence encoding the protein;
[0372] (b) the nucleotide at position -7 is modified as compared to the corresponding position in the natural sequence encoding the protein;
[0373] (c) the nucleotide at position -8 is modified as compared to the corresponding position in the natural sequence encoding the protein;
[0374] (d) the nucleotide at position -9 is modified as compared to the corresponding position in the natural sequence encoding the protein;(e) at least one nucleotide at positions -14 to - 11 is modified as compared to the corresponding position in the natural sequence encoding the protein; (f) at least one nucleotide at positions -15 to - 12 is modified as compared to the corresponding position in the natural sequence encoding the protein; and / or
[0375] (g) at least one nucleotide at positions +9 to + 13 is modified as compared to the corresponding position in the natural sequence encoding the protein, preferably such that the amino acid sequence of the encoded protein is identical to that of the naturally occurring protein.
[0376] 3. The nucleic acid molecule according to any one of the previous clauses wherein the nucleic acid molecule is DNA.
[0377] 4. The nucleic acid molecule according to any one of the previous clauses wherein the nucleic acid molecule is RNA, including mRNA.
[0378] 5. The nucleic acid molecule according to any one of the previous clauses wherein the nucleic acid molecule is comprised in a plasmid, vector or expression construct. 6. The nucleic acid molecule according to any one of the previous clauses wherein:
[0379] (a) the nucleotide at position +6 is modified to a G or U (or corresponding nucleotide when the nucleic acid molecule is DNA), preferably to G; (b) the nucleotide at position -7 is modified to not be G, or wherein the nucleotide at position -7 is modified to a C;
[0380] (c) the nucleotide at position -8 is modified to not be G, or wherein the nucleotide at position -7 is modified to a C;
[0381] (d) the nucleotide at position -9 is modified to a G;
[0382] (e) the nucleotides at positions -14 to - 11 are modified to a WWAA motif (wherein W= U or A);
[0383] (f) the nucleotides at positions -15 to - 12 are modified to a WWAA motif (wherein W= U or A); and / or
[0384] (g) the nucleotides at positions +9 - +13 are modified to not be a AGANT motif (wherein N= A, C, G or U).
[0385] 7. The nucleic acid molecule according to any one of the previous clauses comprising a combination of elements (a) - (g) of clause 2 or elements (a) - (g) of clause 5 selected from the group consisting of (a, b), (a, c), (a, d), (a, e), (a, f), (a, g), (b, c), (b, d), (b, e), (b, f), (b, g), (c, d), (c, e), (c, f), (c, g), (d, e), (d, f), (d, g), (e, f), (e, g), (f, g), (a, b, c), (a, b, d), (a, b, e), (a, b, f), (a, b, g), (a, c, d), (a, c, e), (a, c, f), (a, c, g), (a, d, e), (a, d, f), (a, d, g), (a, e, f), (a, e, g), (a, f, g), (b, c, d), (b, c, e), (b, c, f), (b, c, g), (b, d, e), (b, d, f), (b, d, g), (b, e, f), (b, e, g), (b, f, g), (c, d, e), (c, d, f), (c, d, g),(c, e, f), (c, e, g), (c, f, g), (d, e, f), (d, e, g), (d, f, g), (e, f, g), (a, b, c, d), (a, b, c, e), (a, b, c, f), (a, b, c, g), (a, b, d, e), (a, b, d, f), (a, b, d, g), (a, b, e, f), (a, b, e, g), (a, b, f, g), (a, c, d, e), (a, c, d, f), (a, c, d, g), (a, c, e, f), (a, c, e, g), (a, c, f, g), (a, d, e, f), (a, d, e, g), (a, d, f, g), (a, e, f, g), (b, c, d, e), (b, c, d, f), (b, c, d, g), (b, c, e, f), (b, c, e, g), (b, c, f, g), (b, d, e, f), (b, d, e, g), (b, d, f, g), (b, e, f, g), (c, d, e, f), (c, d, e, g), (c, d, f, g), (c, e, f, g), (d, e, f, g), (a, b, c, d, e), (a, b, c, d, f), (a, b, c, d, g), (a, b, c, e, f), (a, b, c, e, g), (a, b, c, f, g), (a, b, d, e, f), (a, b, d, e, g), (a, b, d, f, g), (a, b, e, f, g), (a, c, d, e, f), (a, c, d, e, g), (a, c, d, f, g), (a, c, e, f, g), (a, d, e, f, g), (b, c, d, e, f), (b, c, d, e, g), (b, c, d, f, g), (b, c, e, f, g), (b, d, e, f, g), (c, d, e, f, g), (a, b, c, d, e, f), (a, b, c, d, e, g), (a, b, c, d, f, g), (a, b, c, e, f, g), (a, b, d, e, f, g), (a, c, d, e, f, g), (b, c, d, e, f, g), and (a, b, c, d, e, f, g).
[0386] The nucleic acid molecule according to any one of the previous clauses wherein the nucleotide at position +6 is modified to a G or U.
[0387] The nucleic acid molecule according to any one of the previous clauses wherein the nucleotides at positions -7 and -8 are both not G, or wherein the nucleotides at position -7 and -8 are both C.
[0388] The nucleic acid molecule according to any one of the previous clauses wherein the nucleotides at position 9 is modified to a G.
[0389] The nucleic acid according to any one of the previous clauses wherein the nucleotides at positions -14 to - 11 are modified to a WWAA motif (wherein W= U or A), or wherein the nucleotides at positions -14 to - 11 are modified to a WWAA motif (wherein W= U or A) and the nucleotides at positions -15 to - 12 are modified to a WWAA motif (wherein W= U or A).
[0390] The nucleic acid molecule according to any one of the previous clauses wherein at least the nucleotide at position +6 is modified to a G or U, preferably to G and the nucleotides at positions -14 to - 11 are modified to a WWAA motif (wherein W= U or A).
[0391] The nucleic acid molecule according to any one of the previous clauses wherein the at least one modification does not change the encoded amino acid.
[0392] The nucleic acid molecule according to any one of the previous clauses wherein the region comprises a Kozak sequence at position -6 - +5, preferably the Kozak sequence being of the form GCCRCCAUGGC (wherein R is A or G, preferably A) (SEQ ID NO: 21).
[0393] The nucleic acid molecule according to any one of the previous clauses wherein the positions -6 - +5 are not modified.The nucleic acid molecule according to any one of the previous clauses wherein the nucleic acid exhibits:
[0394] (a) Increased protein expression (preferably a statistically significant increased protein expression), preferably at least 1.05-fold, preferably at least 1.1-fold, more preferably at least 1.2-fold, or more, increase in protein expression compared to the unmodified sequence in a heterologous expression system; (b) reduced expression of proteins initiated at downstream in-frame or our-of- frame alternative start codons, preferably wherein the alternative start codons are in sequence encoding the protein; and / or
[0395] (c) increased translation efficacy compared to the unmodified sequence, preferably wherein translation efficiency is measured by protein yield per mRNA molecule.
[0396] The nucleic acid molecule according to any one of the previous clauses wherein the nucleic acid is a DNA, RNA or mRNA molecule and wherein the encoded protein is an antigen.
[0397] The nucleic acid molecule according to any one of the previous clauses wherein the nucleic acid further comprises a CAP, preferably a 7-methyl-G cap at the 5’end, a 5' Untranslated Region, a 3' Untranslated Region, and a Poly(A) tail.
[0398] A plasmid, vector, or expression construct comprising the nucleic acid molecule according to any one of the previous clauses.
[0399] A host cell comprising the nucleic acid molecule according to any one of the previous clauses, or comprising a plasmid, vector or expression construct comprising the nucleic acid molecule according to anyone of the previous clauses, preferably wherein the host cell is a eukaryotic cells, preferably an animal cell, more preferably a primate cell, a rodent cell, or, most preferably a human cell, and / or wherein preferably the nucleic acid molecule comprises a transgene coding sequence.
[0400] A vaccine comprising the nucleic acid according to anyone of the previous clauses, and a pharmaceutically acceptable carrier.
[0401] A method of producing a modified nucleic acid molecule encoding a protein of interest, preferably a nucleic acid molecule according to any one of clause 1 - 18, comprising:
[0402] (a) identifying the natural sequence of the nucleic acid encoding the protein, including the region, designated herein as an extended translation initiation site (eTIS), from position -40 to + 40 relative to the first nucleotide of the start codon (designated as +1), and the coding sequence;(b) modifying at least one nucleotide in the region, wherein said nucleotide is different from the natural nucleotide at that position, and preferably such that the amino acid sequence of the encoded protein is identical to that of the naturally occurring protein; and optionally
[0403] (c) synthesizing or expressing the modified nucleic acid.
[0404] The method according to any one of the previous clauses, wherein the modification is as defined in any one of clauses 2 - 18.
[0405] The method according to any one of the previous clauses, wherein the nucleotide at position +6 is modified compared to the corresponding position in the natural sequence encoding the protein;
[0406] (a) the nucleotide at position -7 is modified as compared to the corresponding position in the natural sequence encoding the protein;
[0407] (b) the nucleotide at position -8 is modified as compared to the corresponding position in the natural sequence encoding the protein;
[0408] (c) the nucleotide at position -9 is modified as compared to the corresponding position in the natural sequence encoding the protein;
[0409] (d) at least one nucleotide at positions -14 to - 11 is modified as compared to the corresponding position in the natural sequence encoding the protein; (e) at least one nucleotide at positions -15 to - 12 is modified as compared to the corresponding position in the natural sequence encoding the protein; and / or
[0410] (f) at least one nucleotide at positions +9 to + 13 is modified as compared to the corresponding position in the natural sequence encoding the protein, preferably such that the amino acid sequence of the encoded protein is identical to that of the naturally occurring protein.
[0411] The method according to any one of the previous clauses wherein the nucleic acid molecule is DNA.
[0412] The method according to any one of the previous clauses wherein the nucleic acid molecule is RNA, including mRNA.
[0413] The method according to any one of the previous clauses wherein the nucleic acid molecule is comprised in a plasmid, vector or expression construct.
[0414] The method according to any one of the previous clauses wherein:
[0415] (a) the nucleotide at position +6 is modified to a G or U (or corresponding nucleotide when the nucleic acid molecule is DNA), preferably to G;
[0416] (b) the nucleotide at position -7 is modified to not be G, or wherein the nucleotide at position -7 is modified to a C;(c) the nucleotide at position -8 is modified to not be G, or wherein the nucleotide at position -7 is modified to a C;
[0417] (d) the nucleotide at position -9 is modified to a G;
[0418] (e) the nucleotides at positions -14 to - 11 are modified to a WWAA motif (wherein W= U or A);
[0419] (f) the nucleotides at positions -15 to - 12 are modified to a WWAA motif (wherein W= U or A); and / or
[0420] (g) the nucleotides at positions +9 - +13 are modified to not be a AGANT motif (wherein N= A, C, G or U).
[0421] 29. The method according to any one of the previous clauses wherein a combination of elements (a) - (g) of clause 2 or elements (a) - (g) of clause 5 selected from the group consisting of (a, b), (a, c), (a, d), (a, e), (a, f), (a, g), (b, c), (b, d), (b, e), (b, f), (b, g), (c, d), (c, e), (c, f), (c, g), (d, e), (d, f), (d, g), (e, f), (e, g), (f, g), (a, b, c), (a, b, d), (a, b, e), (a, b, f), (a, b, g), (a, c, d), (a, c, e), (a, c, f), (a, c, g), (a, d, e), (a, d, f), (a, d, g), (a, e, f), (a, e, g), (a, f, g), (b, c, d), (b, c, e), (b, c, f), (b, c, g), (b, d, e), (b, d, f), (b, d, g), (b, e, f), (b, e, g), (b, f, g), (c, d, e), (c, d, f), (c, d, g), (c, e, f), (c, e, g), (c, f, g), (d, e, f), (d, e, g), (d, f, g), (e, f, g), (a, b, c, d), (a, b, c, e), (a, b, c, f), (a, b, c, g), (a, b, d, e), (a, b, d, f), (a, b, d, g), (a, b, e, f), (a, b, e, g), (a, b, f, g), (a, c, d, e), (a, c, d, f), (a, c, d, g), (a, c, e, f), (a, c, e, g), (a, c, f, g), (a, d, e, f), (a, d, e, g), (a, d, f, g), (a, e, f, g), (b, c, d, e), (b, c, d, f), (b, c, d, g), (b, c, e, f), (b, c, e, g), (b, c, f, g), (b, d, e, f), (b, d, e, g), (b, d, f, g), (b, e, f, g), (c, d, e, f), (c, d, e, g), (c, d, f, g), (c, e, f, g), (d, e, f, g), (a, b, c, d, e), (a, b, c, d, f), (a, b, c, d, g), (a, b, c, e, f), (a, b, c, e, g), (a, b, c, f, g), (a, b, d, e, f), (a, b, d, e, g), (a, b, d, f, g), (a, b, e, f, g), (a, c, d, e, f), (a, c, d, e, g), (a, c, d, f, g), (a, c, e, f, g), (a, d, e, f, g), (b, c, d, e, f), (b, c, d, e, g), (b, c, d, f, g), (b, c, e, f, g), (b, d, e, f, g), (c, d, e, f, g), (a, b, c, d, e, f), (a, b, c, d, e, g), (a, b, c, d, f, g), (a, b, c, e, f, g), (a, b, d, e, f, g), (a, c, d, e, f, g), (b, c, d, e, f, g), and (a, b, c, d, e, f, g) is used.
[0422] 30. The method according to any one of the previous clauses wherein the nucleotide at position +6 is modified to a G or U.
[0423] 31 . The method according to any one of the previous clauses wherein the nucleotides at positions -7 and -8 are both not modified to G, or wherein the nucleotides at position -7 and -8 are both modified to C.
[0424] 32. The method according to any one of the previous clauses wherein the nucleotides at position 9 is modified to a G.
[0425] 33. The method according to any one of the previous clauses wherein the nucleotides at positions -14 to - 11 are modified to a WWAA motif (wherein W= U or A), or whereinthe nucleotides at positions -14 to - 11 are modified to a WWAA motif (wherein W= U or A) and the nucleotides at positions -15 to - 12 are modified to a WWAA motif (wherein W= U or A).
[0426] 34. The method according to any one of the previous clauses wherein at least the nucleotide at position +6 is modified to a G or U, preferably to G and the nucleotides at positions -14 to - 11 are modified to a WWAA motif (wherein W= U or A).
[0427] 35. The method according to any one of the previous clauses wherein the at least one modification does not change the encoded amino acid.
[0428] 36. The method according to any one of the previous clauses wherein the region of the modified nucleic acid molecule comprises a Kozak sequence at position -6 - +5, preferably the Kozak sequence being of the form GCCRCCAUGGC (SEQ ID NO: 21) (wherein R is A or G, preferably A).
[0429] 37. The method according to any one of the previous clauses wherein the positions -6 - +5 are not modified.
[0430] 38. The method according to any one of the previous clauses wherein the modified nucleic acid exhibits:
[0431] (a) Increased protein expression, preferably at least 1.05-fold, preferably at least 1.1 -fold, more preferably at least 1.2-fold, or more, increase in protein expression compared to the unmodified sequence in a heterologous expression system;
[0432] (b) reduced expression of proteins initiated at downstream in-frame or our-of- frame alternative start codons, preferably wherein the alternative start codons are in sequence encoding the protein; and / or
[0433] (c) increased translation efficacy compared to the unmodified sequence.
[0434] 39. The method according to any one of the previous clauses wherein the modified nucleic acid is a DNA, RNA or mRNA molecule and wherein the encoded protein is an antigen.
[0435] 40. The method according to any one of the previous clauses wherein the modified nucleic acid further comprises a CAP, preferably a 7-methyl-G cap at the 5’end, a 5' Untranslated Region, a 3' Untranslated Region, and a Poly(A) tail.
[0436] 41 . The method according to any one of the previous clauses wherein the modified nucleic acid is included in a plasmid, vector, or expression construct.
[0437] 42. The method according to any one of the previous clauses wherein the modified nucleic acid is introduced in a host cell, preferably wherein the host cell is a eukaryotic cells, preferably an animal cell, more preferably a primate cell, a rodent cell, or, most preferably a human cell.The method according to any one of the previous clauses wherein the method is for preparing a vaccine comprising a modified nucleic acid according to anyone of the previous clauses, and a pharmaceutically acceptable carrier.
[0438] A method of increasing the expression of a protein in a host cell, comprising:
[0439] (a) introducing into the host cell a nucleic acid molecule according to any one of clauses 1-18 or a plasmid, vector, or expression construct according to clause 19, or providing a host cell according to clause 20, and
[0440] (b) allowing the host cell to transcribe and / or translate the nucleic acid molecule, thereby producing the encoded protein at a level higher compared to the unmodified sequence.
[0441] The method according to clause 44, wherein the increase in expression compared to the unmodified sequence is statistically significant, and / or wherein the increase in expression is at least 1.05-fold, preferably at least 1.1 -fold, more preferably at least 1.2-fold, or more compared to the unmodified sequence in a heterologous expression system.
[0442] A method of reducing expression of (alternative) proteins initiated at downstream inframe or our-of-frame alternative start codons within a nucleic acid molecule, preferably wherein the alternative start codons are in sequence encoding the protein, comprising modifying the nucleic acid molecule according to the any one of the methods according to clauses 22 - 43, thereby preferably favoring expression or translation initiation or translation efficacy at the intended start codon or comprising introducing in a host cell a nucleic acid molecule as defined in any one of clauses 1 -18 or a plasmid, vector, or expression construct according to clause 19, or providing a host cell according to clause 20, and allowing expression of the protein encoded by said nucleic acid thereby preferably favoring expression or translation initiation or translation efficacy at the intended start codon.
[0443] A method for reducing expression of alternative proteins encoded by the nucleic acid, comprising introducing modifications in the nucleic acid according to any one of the methods according to clauses 22 - 43, or a defined in any one of clauses 1 - 18, thereby favoring initiation from said start codon and suppressing initiation from downstream alternative start codons.
[0444] The method according to clause 46 - 47, wherein the modified nucleic acid molecule is a nucleic acid molecule according to any one of clauses 1 - 18 or comprised in a plasmid, vector, or expression construct according to clause 19.The method according to any one of clauses 46 - 48, wherein the modified nucleic acid is a DNA, RNA or mRNA molecule and wherein the encoded protein is an antigen.
[0445] The method according to any one of clauses 46 - 49, wherein the modified nucleic acid further comprises a CAP, preferably a 7-methyl-G cap at the 5’end, a 5' Untranslated Region, a 3' Untranslated Region, and a Poly(A) tail.
[0446] A method of improving translation efficiency of a nucleic acid molecule comprising a start codon and a region, designated herein as an extended translation initiation site (eTIS), from position -40 to + 40 relative to the first nucleotide of the start codon (designated as +1), the method comprising performing the method according to any one of clauses 22 - 43, wherein the translation efficiency of the modified nucleic acid molecules in improved as compared to the unmodified nucleic acid or the method comprising introducing in a host cell a nucleic acid molecule as defined in any one of clauses 1 - 18 or a plasmid, vector, or expression construct according to clause 19, or providing a host cell according to clause 20, and allowing expression of the protein encoded by said nucleic acid,
[0447] preferably wherein translation efficiency is measured by protein yield per mRNA molecule.
[0448] A method according to any one of the previous clauses wherein the method is performed ex vivo, in vitro or in vivo.
[0449] Use of a nucleic acid according to any one of clauses 1 to 18 or obtained according to any one of clauses 22 - 43 in the manufacture of a medicament.
[0450] The nucleic acid molecule according to anyone of the previous clauses, or the method according to anyone of the previous clauses, wherein the modification is a substitution.
[0451] The nucleic acid molecule according to anyone of the previous clauses, or the method according to anyone of the previous clauses, wherein the nucleic acid molecule comprises a sequence as disclosed in any of the figures.
Claims
CLAIMS1. A method of modifying the sequence of a nucleic acid,wherein the nucleic acid to be modifiedi. comprises a first region having a sequence encoding for a protein-of- interest, and wherein the first region comprises a translation initiation codon (“TIC” or “start codon”), and wherein the position of the first nucleotide in the TIC is designated as +1, andii. comprises a second region having a sequence that is directly upstream of the first region, and wherein the position of the first nucleotide upstream off the first region is designated as -1 , andiii. comprises a translation initiation sequence (“TIS”), wherein the TIS spans positions designated as -6 to -1 (being upstream of the TIC) and designated as +4 to +5 (being downstream of the TIC), andiv. comprises an extended initiation sequence (“eTIS”), wherein the eTIS spans positions from -80 to +80 relative to the first nucleotide of the TIC, and wherein the method comprises modifying the sequence of the nucleic acid at one or more nucleotides of the TIS and / or the eTIS, thereby providing a modified nucleic acid.
2. The method of claim 1, which comprises an extended initiation sequence (“eTIS”), wherein the eTIS spans positions -51 to -1 (being upstream of the TIC), more preferably -40 to -1 (being upstream of the TIC) and +4 to +40 (being downstream of the TIC), or wherein the eTIS spans positions from -40 to +40 relative to the first nucleotide of the TIC.
3. The method of any one of the previous claims wherein the modified nucleic acid is present in a eukaryotic cell, preferably an animal cell or human cell, or wherein the modified nucleic acid is introduced in a eukaryotic cell, preferably an animal cell or human cell.
4. The method of any one of the previous claims, wherein the modification does not change the amino acid sequence of the encoded protein-of-interest.
5. The method of any one of the previous claims wherein(a) the modified nucleic acid, or eukaryotic cell comprising the modified nucleic acid, exhibits increased expression of the protein-of-interest as compared to the unmodified nucleic acid;(b) the modified nucleic acid, or eukaryotic cell comprising the modified nucleic acid, exhibits reduced expression of alternative proteins initiated at downstream in-frame or out of frame alternative TICs, preferably wherein the alternative TICs are present in the sequence encoding the protein-of interest; and / or(c) the modified nucleic acid, or eukaryotic cell comprising the modified nucleic acid, exhibits increased translation efficacy as compared to the unmodified nucleic acid.
6. The method of any one of the previous claims wherein the nucleic acid and / or modified nucleic acid is a recombinant nucleic acid, and / or wherein the nucleic acid and / or modified nucleic acid is a RNA molecule, preferably mRNA molecule, or DNA molecule, preferably a DNA molecule encoding the RNA molecule, more preferably wherein the nucleic acid and / or modified nucleic acid is a therapeutic nucleic acid, preferably a therapeutic DNA molecule, a therapeutic RNA molecule, or a therapeutic mRNA molecule.
7. The method of any one of the previous claims wherein the nucleic acid or modified is comprised in a plasmid, vector or expression construct.
8. The method of any one of the previous claims wherein the protein-of-interest is an antigen.
9. The method of any one of the previous claims, wherein one or more of:(a) a U, C or G at one or more of the positions -14 to -9 in the nucleic acid is modified to an A;(b) an A, C or G at one or more of the positions -35 to -18 in the nucleic acid is modified to an U;(c) a U, C or G at one or more of the positions +12 to +18 in the nucleic acid is modified to an A; and / or(d) an A, U or C at one or more of the positions +9 to +11 in the nucleic acid is modified to a G,or wherein the modified nucleic acid comprises(e) an A at one or more of the positions -14 to -9;(f) a U at one or more of the positions -35 to -18;(g) an A at one or more of the positions +12 to +18; and or(h) a G at one or more of the positions +9 to +1110. The method of any one of the previous claims, wherein one or more nucleotides are modified, and wherein the nucleotide at a first position indicated in Tables 1 - 3is modified to a nucleotide for which a lower value is indicated at the corresponding position in any one of Table 1 , Table 2 or Table 3.
11. The method according to any one of the previous claims, wherein the sequence of the TIS and TIC in the nucleic acid is modified to ACCACA ATG GC (SEQ ID NO: 1) or, preferably, ACCAAA ATG GC (SEQ ID NO: 2), or wherein the sequence of the TIS and TIC in the modified nucleic acid is ACCACA ATG GC (SEQ ID NO: 1) or, preferably, ACCAAA ATG GC (SEQ ID NO: 2).
12. The method according to any one of the previous claims wherein the nucleic acid is modified to comprise, or wherein the modified nucleic acid comprises one or more of:(a) a G or T, preferably G, at position +6;(b) a C or G, preferably C, at position +9;(c) a A or C, preferably A, at position +12;(d) a G or C, preferably G, at position +15;(e) a A or C, preferably A, at position +18;(f) a C or A, preferably C, at position +21 ;(g) a G or C, preferably G, at position +24;(h) a T or G, preferably T, as position +27;(i) a G or C, preferably C, at position +30;(j) a T or G, preferably T, at position + 33;(k) a AAA motif at position +16 to +18;(l) a CCC motif at position +7 to +9;(m) a CTAAA motif at position +10 to +14;(n) a AAAAA motif at position -14 to -10; and / or(o) a UUUUUUUUUUU (SEQ ID NO: 16) motif at position -37 to -27(p) a ATT motif at position -9 to -7; and / or13. The method according to any one of the previous claims wherein the nucleic acid is modified to comprise, or wherein the modified nucleic acid comprises:(a) a sequenceGAATTTTTAATTTCTTTTATTTTTAAAT ATT AT AT AAAAAAAATT ACCAAA at positions -51 to -1 (SEQ ID NO: 3);(b) a sequence TTCTTTTATTTTTAAATATTATATAAAAAAAATTACCAAA at positions -40 to -1 (SEQ ID NO: 4);(c) a sequenceGAATTTTTAATTTCTTTTATTTTTAAAT ATT AT AT AAAAAAAATT ACCAAAATG NN(G / T)NN(C / G)NN(A / C)NN(G / C)NN(A / C)NN(C / A)NN(G / C)NN(T / G)NN(G / C)NN(T / G) (SEQ ID NO: 5) at positions -51 to +33, wherein a N indicates any one of A, T, C or G.(d) A sequence at positions -51 to +33 GAATTTTTAATTTCTTTTATTTTTAAATATTATATAAAAAAAATTACCAAAATG GCGCCCTTAAAGAAATACAGGCCTCCGGCT (SEQ ID NO: 6)14. A method of increasing protein expression of a protein-of-interest, the method comprising modifying a nucleic acid according to any one of claims 1 - 12, thereby providing a modified nucleotide, and allowing expression of the protein-of-interest using the modified nucleic acid, thereby allowing increased expression of the protein of interest as compared to the unmodified nucleic acid.
15. A method of reducing expression of alternative proteins initiated at downstream of the TIC of the protein-of-interest in-frame out of frame alternative TICs, preferably wherein the alternative TICs are present in the sequence encoding the protein-of interest, the method comprising modifying a nucleic acid according to any one of claims 1 - 13, thereby providing a modified nucleotide, and allowing expression of the protein-of-interest using the modified nucleic acid, thereby favoring translation initiation from the TIC of the protein-of-interest and reducing translation initiation from the alternative TICs.
16. A method of increasing protein expression of a protein-of-interest and / or of reducing expression of alternative proteins nitiated at in-frame or out of frame alternative TICs downstream of the TIC of the protein-of-interest, the method comprising:(a) identifying the natural sequence of the nucleic acid encoding the protein of interest, and including the TIC, TIS and eTIS;(b) modifying the natural sequence of the nucleic acid in accordance with any one of claims 1-13, thereby providing a modified nucleic acid; and(c) optionally, allowing expression of the modified nucleic acid.
17. A modified nucleic acid as defined in any one of claims 1 - 16, preferably wherein the sequence of the TIS and TIC in the modified nucleic acid is as defined in claim 11 , and / or wherein the modified nucleic acid comprises a sequence as defined in claim 13a, 13b or 13c, and / or wherein the modified nucleic acid comprises one or more of the motifs as defined in claim 12k -12o.
18. The modified nucleic acid according to claim 17, wherein:(a) the nucleotide at position +6 is modified compared to the corresponding position in the natural sequence encoding the protein;(b) the nucleotide at position -7 is modified as compared to the corresponding position in the natural sequence encoding the protein;(c) the nucleotide at position -8 is modified as compared to the corresponding position in the natural sequence encoding the protein;(d) the nucleotide at position -9 is modified as compared to the corresponding position in the natural sequence encoding the protein;(e) at least one nucleotide at positions -14 to - 11 is modified as compared to the corresponding position in the natural sequence encoding the protein; (f) at least one nucleotide at positions -15 to - 12 is modified as compared to the corresponding position in the natural sequence encoding the protein; and / or(g) at least one nucleotide at positions +9 to + 13 is modified as compared to the corresponding position in the natural sequence encoding the protein, preferably such that the amino acid sequence of the encoded protein is identical to that of the naturally occurring protein.
19. The modified nucleic acid according to claim 17-18, wherein:(a) the nucleotide at position +6 is modified to a G or U (or corresponding nucleotide when the nucleic acid molecule is DNA), preferably to G;(b) the nucleotide at position -7 is modified to not be G, or wherein the nucleotide at position -7 is modified to a C;(c) the nucleotide at position -8 is modified to not be G, or wherein the nucleotide at position -8 is modified to a C;(d) the nucleotide at position -9 is modified to a G;(e) the nucleotides at positions -14 to - 11 are modified to a WWAA motif (wherein W= U or A);(f) the nucleotides at positions -15 to - 12 are modified to a WWAA motif (wherein W= U or A); and / or(g) the nucleotides at positions +9 - +13 are modified to not be a AGANT motif (wherein N= A, C, G or U).
20. The modified nucleic acid according to claim 17-19, wherein the TIS as defined in claim 1 comprises a Kozak sequence at position -6 - +5, preferably the Kozak sequence being of the form GCCRCCAUGGC (SEQ ID NO: 21 ), wherein R is A or G, preferably A.
21. A cell, plasmid, expression construct, vector, (m)RNA, vaccine or pharmaceutical composition comprising a modified nucleic acid as defined in any one of claim 1 - 20; or a host cell comprising a plasmid, vector or expression construct comprisingthe modified nucleic acid molecule as defined in any one of the previous claim 1 - 20, preferably wherein the host cell is a eukaryotic cells, preferably an animal cell, more preferably a primate cell, a rodent cell, or, most preferably a human cell, and / or wherein preferably the nucleic acid molecule comprises a transgene coding sequence.
22. A method of manufacturing a pharmaceutical composition comprising a modified nucleic acid or a protein-of-interest, the method comprising modifying a nucleic acid according to method of any one of claim 1 - 15, thereby providing a modified nucleic acid, and including the modified nucleic acid, or the protein-of-interest expressed therefrom, in the pharmaceutical composition.
23. A computational-implemented method or algorithm for training a deep convolutional neural network (DCNN) to predict translation-initiation activity of a nucleic acid sequence, preferably including positions -100 to + 50, more preferably -90 to + 40, even more preferably -51 to + 40, or - 80 to + 80, or - 40 to + 40, or part thereof of at least 15 nucleotides, preferably at least 20 nucleotides, preferably including a TIC, the method or algorithm comprising, by one or more processors:1) receiving, from a memory, a dataset comprising a plurality of nucleic acid sequence measurement records, each associating a measured translationinitiation activity value obtained from a massively parallel reporter assay (MPRA);2) preprocessing the plurality of nucleic acid sequences to generate digital sequence representations suitable for neural network input;3) training the DCNN using the digital sequence representations as inputs and the measured translation-initiation activity values as supervised targets, wherein the DCNN learns to map sequence context to translation-initiation activity by optimizing a loss function that quantifies prediction error; and4) storing the trained DCNN model parameters in a non-transitory computer- readable storage medium.
24. A computer-implemented method for predicting translation-initiation activity of a nucleic acid sequence, preferably including positions -100 to + 50, more preferably -90 to + 40, even more preferably -51 to + 40, or - 80 to + 80, or - 40 to + 40, or part thereof of at least 15 nucleotides, preferably at least 20 nucleotides, preferably including a TIC, the method comprising, by one or more processors: 1) receiving a trained deep convolutional neural network (DCNN) model previously trained to map sequence context to translation-initiation activity, preferably the DCNN model obtained according to the method of claim 19;2) receiving one or more query nucleic acid sequences, preferably not present in the training dataset;3) optionally, preprocessing the query sequences to generate digital sequence representations suitable for input to the trained DCNN;4) applying the trained DCNN to the one or more query nucleic acid sequences or digital representations to generate predicted translation-initiation activity values for the query sequences;5) optionally identifying one or more regulatory sequence motifs contributing to translation-initiation activity by analysing the trained DCNN using a model- interpretation technique;6) outputting the predicted translation-initiation activity values and, optionally, the identified regulatory motifs. / / end
